UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from: _____________ to _____________
KYTO BIOPHARMA,TECHNOLOGY AND LIFE SCIENCE, INC.
(Exact name of registrant as specified in its charter)
| 000-50390 | 65-1086538 | |||
| (State or Other Jurisdiction | (Commission | (I.R.S. Employer | ||
| of Incorporation) | File Number) | Identification No.) |
13050 Paloma Road, Los Altos Hills, CA94022
(Address of Principal Executive Office) (Zip Code)
(650)204 7896
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
| Title of each class | Trading Symbol | Exchange | ||
| Common stock | KBPH | OTC QB |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ ☒ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss. 232.405 of this chapter) during the preceding 12 (or for such shorter period that the registrant was required to submit and post such files). ☒ Yes No☐ Yes ☑ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |
| Non-accelerated filer | ☐ | Smaller reporting company | ||
| Emerging | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☑ ☒ No
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Shares - $0.0001$.01 Par Value - as of
KYTO BIOPHARMA, INC.
For the quarterly period ended December 31, 2017
INDEX
| 2 |
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Kyto Biopharma, Inc. | ||
Condensed Balance Sheets | ||
December 31, | March 31, | |
2017 | 2017 | |
(Unaudited) | ||
| ASSETS | ||
| Current Assets | ||
| Cash | $76 | $- |
| Total Current Assets | 76 | - |
| Total Assets | $76 | $- |
LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
| Current Liabilities | ||
| Accounts payable and accrued expenses | $- | $22 |
| Accrued liabilities | 5,000 | 10,000 |
| Accrued liabilities - related party | 196,000 | 148,000 |
| Loans payable - related party | 89,067 | 68,107 |
| Total Current Liabilities | 290,067 | 226,129 |
| Commitments and Contingencies | ||
| Stockholders' Deficit | ||
| Preferred convertible stock, $1.00 par value, 2,000,000 shares | ||
| authorized, none issued and outstanding as of | ||
| December 31, 2017 and March 31, 2017, respectively | - | - |
| Common stock, $0.0001 par value, 100,000,000 shares | ||
| authorized, 3,139,747 issued and outstanding as of | ||
| December 31, 2017 and March 31, 2017, respectively | 314 | 314 |
| Additional paid-in capital | 32,063,476 | 32,063,476 |
| Accumulated deficit | (32,353,781) | (32,289,919) |
| Total Stockholders' Deficit | (289,991) | (226,129) |
| Total Liabilities and Stockholders' Deficit | $76 | $- |
Kyto Technology and Life Science, Inc.
Condensed Statements of Assets and Liabilities
| September 30, | March 31, | |||||||
| 2021 | 2021 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Investments at fair value (cost of $7,904,636 and $5,686,545, respectively) | $ | 10,442,813 | $ | 6,821,407 | ||||
| Cash | 316,124 | 1,437,868 | ||||||
| Other current assets | 230,434 | 169,891 | ||||||
| Total Assets | $ | 10,989,371 | $ | 8,429,166 | ||||
| LIABILITIES | ||||||||
| Liabilities | ||||||||
| Accounts payable and accrued liabilities | $ | 84,477 | $ | 193,141 | ||||
| Accrued liabilities - related parties | 87,000 | 51,420 | ||||||
| Common stock subscription liability | - | 1,191,442 | ||||||
| Total Liabilities | 171,477 | 1,436,003 | ||||||
| Commitments and Contingencies (Note 3) | - | - | ||||||
| Net Assets | ||||||||
| Preferred stock authorized but not designated, $ par value shares, issued and outstanding as of September 30, 2021 and March 31, 2021, respectively | - | - | ||||||
| Series A (including Series A-1 and A-2) preferred convertible stock, $par value, shares designated, issued and outstanding as of September 30, 2021 and March 31, 2021, respectively, aggregate liquidation preference of $6,720,000 at September 30, 2021 and March 31, 2021, respectively | 42,001 | 42,001 | ||||||
| Series B (including Series B-1 and B-2) preferred convertible stock, $par value, shares designated, and issued and outstanding as of September 30, 2021 and March 31, 2021, respectively, aggregate liquidation preference of $9,458,250 at September 30, 2021 and $5,806,250 at March 31, 2021, respectively | 59,114 | 36,289 | ||||||
| Preferred stock, value | - | - | ||||||
| Common stock, $ par value, shares authorized, and issued and outstanding as of September 30, 2021 and March 31 2021, respectively | 132,876 | 99,831 | ||||||
| Additional paid-in capital | 42,878,748 | 39,772,228 | ||||||
| Accumulated deficit | (32,294,845 | ) | (32,957,186 | ) | ||||
| Total Net Assets | 10,817,894 | 6,993,163 | ||||||
| Total Liabilities and Net Assets | $ | 10,989,371 | $ | 8,429,166 | ||||
The accompanying notes are an integral part of these unaudited condensed interim financial statements.
| 3 |
Kyto Biopharma, Inc. | ||||
Condensed Statements of Operations | ||||
(Unaudited) | ||||
For the Three Months Ended | For the Nine Months Ended | |||
Dember 31, 2017 | December 31 | |||
2017 | 2016 | 2017 | 2016 | |
| Operating Expenses | ||||
| General and administrative | $24,133 | $31,079 | $63,862 | $70,135 |
| Total Operating Expenses | 24,133 | 31,079 | 63,862 | 70,135 |
| Loss from Operations | 24,133 | 31,079 | 63,862 | 70,135 |
| Net Loss before taxes | (24,133) | (31,079) | (63,862) | (70,135) |
| Net Income (Tax) Benefit | - | - | - | - |
| Net Loss | $(24,133) | $(31,079) | $(63,862) | $(70,135) |
| Weighted average number of shares outstanding | ||||
| basic and diluted | 3,139,747 | 3,139,747 | 3,139,747 | 3,139,747 |
| Net loss per share - basic and diluted | $(0.01) | $(0.01) | $(0.02) | $(0.02) |
Kyto Technology and Life Science, Inc.
Condensed Statements of Operations
(Unaudited)
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| For the Three months ended September 30, | For the Six months ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| INVESTMENT INCOME | ||||||||||||||||
| Interest and other income | $ | - | $ | - | $ | - | $ | 500 | ||||||||
| Total investment income | - | - | - | 500 | ||||||||||||
| EXPENSES | ||||||||||||||||
| Professional fees | 107,201 | 63,605 | 273,359 | 76,543 | ||||||||||||
| Other operating expenses | 245,519 | 96,506 | 466,027 | 122,936 | ||||||||||||
| Interest and non operating expenses | 1,596 | - | 1,588 | - | ||||||||||||
| Total expenses | 354,316 | 160,111 | 740,974 | 199,479 | ||||||||||||
| Net investment loss | (354,316 | ) | (160,111 | ) | (740,974 | ) | (198,979 | ) | ||||||||
| Net change in unrealized gain from investments | 1,350,449 | 478,248 | 1,403,315 | 478,248 | ||||||||||||
| Net increase in net assets resulting from operations | $ | 996,133 | $ | 318,137 | $ | 662,341 | $ | 279,269 | ||||||||
| Basic earnings per Common Share, | ||||||||||||||||
| Net increase in net assets resulting from operations per common share | $ | 0.08 | $ | 0.05 | $ | 0.05 | $ | 0.05 | ||||||||
| Weighted average common shares outstanding | 13,271,996 | 5,836,832 | 13,269,764 | 5,836,832 | ||||||||||||
| Fully-diluted earnings per Common Share, | ||||||||||||||||
| Net increase in net assets resulting from operations per common share | $ | 0.04 | $ | 0.02 | $ | 0.03 | $ | 0.02 | ||||||||
| Weighted average common shares outstanding | 27,338,695 | 17,987,040 | 26,263,218 | 17,058,856 | ||||||||||||
The accompanying notes are an integral part of these unaudited condensed interim financial statements.
| 4 |
Kyto Biopharma, Inc. | |||||||
Condensed Statement of Stockholder's Deficit | |||||||
For the Nine Months Ended December 31, 2017 | |||||||
(Unaudited) | |||||||
Preferred Stock | Common Stock | Additional | |||||
$1.00 par value | $0.0001 par value | Paid - in | Accumulated | ||||
Shares | Amount | Shares | Amount | Capital | Deficit | Total | |
| Balance, March 31, 2017 | - | $- | 3,139,747 | $314 | $32,063,476 | $(32,289,919) | $(226,129) |
| Net Loss | - | - | - | - | - | (63,862) | (63,862) |
| Balance, December 31, 2017 | - | $- | 3,139,747 | $314 | $32,063,476 | $(32,353,781) | $(289,991) |
Kyto Technology and Life Science, Inc.
Condensed Statements of Changes in Net Assets for the Three and Six months ended September 30, 2021
( Unaudited)
| Preferred A | Preferred B | Common | Additional | |||||||||||||||||||||||||||||||||
| Preferred A (Including Series A-1, A-2) | Preferred A Stock (Including Series A-1, A-2) | Preferred B (Including Series B-1, B-2) | Preferred B (Including Series B-1, B-2) Stock | Common | Common Stock | Additional Paid-in | Accumulated | |||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Total | ||||||||||||||||||||||||||||
| Three months ended September 30, 2021 | ||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2021 | 4,200,000 | $ | 42,001 | 4,320,156 | $ | 43,202 | 13,268,871 | $ | 132,689 | $ | 41,610,332 | $ | (33,290,978 | ) | $ | 8,537,246 | ||||||||||||||||||||
| Net increase in net assets resulting from operations | 996,133 | 996,133 | ||||||||||||||||||||||||||||||||||
| Sale of Series B-1 Preferred stock at $per share | - | - | 1,591,250 | 15,912 | 1,257,088 | 1,273,000 | ||||||||||||||||||||||||||||||
| Sale of common stock at $0.40 per share | ||||||||||||||||||||||||||||||||||||
| Sale of common stock at $0.40 per share, shares | ||||||||||||||||||||||||||||||||||||
| Exercise of stock options | 18,750 | 187 | 431 | 618 | ||||||||||||||||||||||||||||||||
| Compensation expense from stock options | 10,897 | 10,897 | ||||||||||||||||||||||||||||||||||
| Balance, September 30, 2021 | 4,200,000 | $ | 42,001 | 5,911,406 | $ | 59,114 | 13,287,621 | $ | 132,876 | $ | 42,878,748 | $ | (32,294,845 | ) | $ | 10,817,894 | ||||||||||||||||||||
| Six months ended September 30, 2021 | ||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2021 | 4,200,000 | $ | 42,001 | 3,628,906 | $ | 36,289 | 9,983,082 | $ | 99,831 | $ | 39,772,228 | $ | (32,957,186 | ) | $ | 6,993,163 | ||||||||||||||||||||
| Net increase in net assets resulting from operations | 662,341 | 662,341 | ||||||||||||||||||||||||||||||||||
| Sale of Series B-1 Preferred stock at $per share | - | - | 2,282,500 | 22,825 | 1,803,176 | 1,826,001 | ||||||||||||||||||||||||||||||
| Sale of common stock at $ per share | 3,285,789 | 32,858 | 1,281,459 | 1,314,317 | ||||||||||||||||||||||||||||||||
| Exerrcise of stock options | 18,750 | 187 | 431 | 618 | ||||||||||||||||||||||||||||||||
| Compensation expense from stock options | 21,454 | 21,454 | ||||||||||||||||||||||||||||||||||
| Balance, September 30, 2021 | 4,200,000 | $ | 42,001 | 5,911,406 | $ | 59,114 | 13,287,621 | $ | 132,876 | $ | 42,878,748 | $ | (32,294,845 | ) | $ | 10,817,894 | ||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed interim financial statements.
| 5 |
Kyto Biopharma, Inc. | ||
Condensed Statements of Cash Flows | ||
(Unaudited) | ||
For the Nine Months Ended December 31, | ||
2017 | 2016 | |
| Cash Flows from Operating Activities: | ||
| Net loss | $(63,862) | $(70,135) |
| Adjustment to reconcile net loss to net cash used in operating activities: | ||
| Changes in operating liabilities: | ||
| Accrued liabilities - related party | 48,000 | 48,000 |
| Accrued liabilities | (5,000) | (7,500) |
| Accounts payable and accrued expenses | (22) | 326 |
| Net Cash Used in Operating Activities | (20,884) | (29,309) |
| Cash Flows from Investing Activities: | ||
| Net Cash Used in Investing Activities | - | - |
| Cash Flows from Financing Activities: | ||
| Loan proceeds from related parties, net | 20,960 | 29,286 |
| Net Cash Provided by Financing Activities | 20,960 | 29,286 |
| Net increase (decrease) in Cash and Cash Equivalents | 76 | (23) |
| Cash and Cash Equivalents at Beginning of Period | - | 32 |
| Cash and Cash Equivalents at End of Period | $76 | $9 |
| Supplemental Disclosure of Cash Flow Information: | ||
| Cash paid for: | ||
| Interest | $- | $- |
| Income taxes | $- | $- |
Kyto Technology and Life Science, Inc.
Condensed Statements of Changes in Net Assets for the Three and Six months ended September 30, 2020
( Unaudited)
| Preferred A | Preferred A Stock | Preferred B | Preferred B Stock | Common | Common Stock | Additional Paid-in | Accumulated | |||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Total | ||||||||||||||||||||||||||||
| Three months ended September 30, 2020 | ||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2020 | 42,000,000 | $ | 42,001 | 1,281,250 | $ | 12,188 | 5,836,832 | $ | 58,368 | $ | 36,315,354 | $ | (33,423,120 | ) | $ | 3,004,791 | ||||||||||||||||||||
| Net increase in net assets resulting from operations | - | - | - | - | - | - | - | 318,137 | 318,137 | |||||||||||||||||||||||||||
| Sale of Series B Preferred stock at $ per share | - | - | 1,056,250 | 11,187 | - | - | 883,813 | - | 895,000 | |||||||||||||||||||||||||||
| Compensation expense from stock options | - | - | - | - | - | - | 12,803 | - | 12,803 | |||||||||||||||||||||||||||
| Balance, September 30, 2020 | 42,000,000 | $ | 42,001 | 2,337,500 | $ | 23,375 | 5,836,832 | $ | 58,368 | $ | 37,211,970 | $ | (33,104,983 | ) | $ | 4,230,731 | ||||||||||||||||||||
| Six months ended September 30, 2020 | ||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2020 | 42,000,000 | $ | 42,001 | 812,500 | $ | 8,125 | 5,836,832 | $ | 58,368 | $ | 35,943,369 | $ | (33,384,252 | ) | $ | 2,667,611 | ||||||||||||||||||||
| Balance | 42,000,000 | $ | 42,001 | 812,500 | $ | 8,125 | 5,836,832 | $ | 58,368 | $ | 35,943,369 | $ | (33,384,252 | ) | $ | 2,667,611 | ||||||||||||||||||||
| Net increase in net assets resulting from operations | - | - | - | - | - | - | - | 279,269 | 279,269 | |||||||||||||||||||||||||||
| Sale of Series B Preferred stock at $ per share | - | - | 1,525,000 | 15,250 | - | - | 1,254,750 | - | 1,270,000 | |||||||||||||||||||||||||||
| Compensation expense from stock options | - | - | - | - | - | - | 13,851 | - | 13,851 | |||||||||||||||||||||||||||
| Balance, September 30, 2020 | 42,000,000 | $ | 42,001 | 2,337,500 | $ | 23,375 | 5,836,832 | $ | 58,368 | $ | 37,211,970 | $ | (33,104,983 | ) | $ | 4,230,731 | ||||||||||||||||||||
| Balance | 42,000,000 | $ | 42,001 | 2,337,500 | $ | 23,375 | 5,836,832 | $ | 58,368 | $ | 37,211,970 | $ | (33,104,983 | ) | $ | 4,230,731 | ||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed interim financial statements.
| 6 |
Kyto Technology and Life Science, Inc.
Condensed Statements of Cash Flows
(Unaudited)
| 2021 | 2020 | |||||||
Six months months ended September 30, | ||||||||
| 2021 | 2020 | |||||||
| Operating activities: | ||||||||
| Net increase in net assets resulting from operations | $ | 662,341 | $ | 279,269 | ||||
| Adjustments to reconcile net increase (decrease) in net assets resulting from operations to net cash used in operating activities | ||||||||
| Net change in unrealized gain on investments | (1,403,315 | ) | (478,248 | ) | ||||
| Stock option compensation expense | 21,454 | 13,851 | ||||||
| Change in operating assets and liabilities | ||||||||
| Other current assets | (60,543 | ) | 500 | |||||
| Accounts payable and accrued liabilities | (108,664 | ) | 15,064 | |||||
| Accrued liabilities to related parties | 35,580 | - | ||||||
| Purchase of investments | (2,218,091 | ) | (740,000 | ) | ||||
| Net cash used in operating activities | (3,071,238 | ) | (909,564 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Sale of Common stock in connection with preference rights (see Note 6) | 122,875 | - | ||||||
| Sale of Common stock from exercise of options stock | 618 | - | ||||||
| Sale of Series B-1 Preferred stock | 1,826,001 | 1,270,000 | ||||||
| Receipt of SBA loan | - | 1,000 | ||||||
| Advances from related party | - | 2,250 | ||||||
| Net cash provided by financing activities | 1,949,494 | 1,273,250 | ||||||
| Net increase/(decrease) in cash | (1,121,744 | ) | 363,686 | |||||
| Cash, beginning of period | 1,437,868 | 33,756 | ||||||
| Cash, end of period | $ | 316,124 | $ | 397,442 | ||||
| Supplemental cash flow information | ||||||||
| Interest paid | $ | 1,588 | $ | - | ||||
| Taxes paid | $ | 800 | $ | 800 | ||||
| Supplemental schedule of noncash financing activities: | ||||||||
| Conversion of common stock subscription liability to common stock | $ | 1,191,442 | $ | - | ||||
The accompanying notes are an integral part of these condensed interim financial statements.
| 7 |
Kyto Technology and Life Science, Inc.
Condensed Schedule of Investments as of September 30, 2021
(Unaudited)
| Portfolio Company | Industry | Investment | Cost | Fair value | % of net assets (a) | ||||||||||||||
| Convertible loan investments | |||||||||||||||||||
| Abfero Pharmaceuticals Inc | Life science | Convertible Note, 6% due, December 2022 | $ | 100,000 | $ | 102,630 | 0.9 | % | |||||||||||
| ( i ) | Achelios Therapeutics Inc. | Life science | Convertible Note, 8% due, December 2021 | 100,000 | 125,184 | 1.2 | % | ||||||||||||
| ( i ) | Achelios Therapeutics Inc. | Life science | Convertible Note, 8% due December 2021 | 25,000 | 30,036 | 0.3 | % | ||||||||||||
| ( i ) | Achelios Therapeutics Inc. | Life science | Convertible Note, 8% due December 2021 | 50,000 | 56,586 | 0.5 | % | ||||||||||||
| ( i ) | Achelios Therapeutics Inc. | Life science | Convertible Note Sidecar, 25% discount. No interest | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| AOA DX Inc | Life science | Convertible Note, 4%, due May 2024 | 100,000 | 101,567 | 0.9 | % | |||||||||||||
| Avisi Technologies Inc | Life science | Convertible Note, 8% due July 2022 | 50,000 | 54,679 | 0.5 | % | |||||||||||||
| Basepaws Inc | Life science | Convertible Note, 1% due April 2020 | 50,000 | 201,663 | 1.9 | % | |||||||||||||
| ( i ) | Beam Semiconductor Inc | * | Technology | Convertible Note, 8% due April 2022 | 150,000 | 177,058 | 1.6 | % | |||||||||||
| ( i ) | Beam Semiconductor Inc | * | Technology | Convertible Note, 8% due March 2021 | 50,000 | 56,290 | 0.5 | % | |||||||||||
| ( i ) | Beam Semiconductor Inc | * | Technology | Convertible Note, 8% due March 2022 | 100,000 | 103,704 | 1.0 | % | |||||||||||
| CoLabs Inc | Life science | Convertible Note, 6% due February 2023 | 50,000 | 50,304 | 0.5 | % | |||||||||||||
| Corinnova Inc | Life science | Convertible Note, 6% due December 2024 | 100,000 | 105,211 | 1.0 | % | |||||||||||||
| Corinnova Inc | Life science | Convertible Note, 6% due December 2024 | 50,000 | 50,164 | 0.5 | % | |||||||||||||
| * | Cyberdontics Inc | * | Life science | Convertible Note, 8% due September 2022 | 30,000 | 34,971 | 0.3 | % | |||||||||||
| * | Cyberdontics Inc | * | Life science | Convertible Note, 8% due February 2023 | 35,000 | 39,457 | 0.4 | % | |||||||||||
| * | Cyberdontics Inc | * | Life science | Convertible Note, 0% no due date | 35,000 | 37,700 | 0.3 | % | |||||||||||
| Deep Blue Medical Advances Inc | Life science | Convertible Note, 6% due June 2022 | 50,000 | 52,351 | 0.5 | % | |||||||||||||
| Every Key Inc | Technology | Convertible Note, 5% due December 2023 | 100,000 | 109,027 | 1.0 | % | |||||||||||||
| Identical Inc | Life science | Convertible Note, 2% due May 2022 | 100,000 | 101,775 | 0.9 | % | |||||||||||||
| * | INBay Technology Inc | Technology | Convertible Note, 12% due October 2020 | 50,000 | 67,589 | 0.6 | % | ||||||||||||
| * | INBay Technology Inc | Technology | Convertible Note, 12% due July 2021 | 30,000 | 38,028 | 0.4 | % | ||||||||||||
| * | INBay Technology Inc | Technology | Convertible Note, 12% due February 2022 | 50,000 | 59,649 | 0.6 | % | ||||||||||||
| * | INBay Technology Inc | Technology | Convertible Note, 12% due December 2022 | 40,000 | 43,958 | 0.4 | % | ||||||||||||
| * | INBay Technology Inc | Technology | Convertible Note, 12% due December 2023 | 50,000 | 52,926 | 0.5 | % | ||||||||||||
| * | Iris R&D Group Inc | Technology | Convertible Note, 8% May 2023 | 50,000 | 51,447 | 0.5 | % | ||||||||||||
| Kiana Analytics Inc | Technology | Convertible Note, 3% December 2022 | 100,000 | 102,326 | 0.9 | % | |||||||||||||
| Kitotech Medical Inc | Life science | Convertible Note, 6% due December 2020 | 100,000 | 246,141 | 2.3 | % | |||||||||||||
| Kitotech Medical Inc | Life science | Convertible Note, 6% due November 2022 | 75,000 | 85,896 | 0.8 | % | |||||||||||||
| Lifewave Biomedical Inc | Life science | Convertible Note, 6% due December 2020 | 30,000 | 33,733 | 0.3 | % | |||||||||||||
| Lifewave Biomedical Inc | Life science | Convertible Note, 6% due December 2020 | 70,000 | 76,916 | 0.7 | % | |||||||||||||
| Lifewave Biomedical Inc | Life science | Convertible Note, 6% due December 2021 | 50,000 | 51,159 | 0.5 | % | |||||||||||||
| Lowell Therapeutics Inc | Life science | Convertible Note, 8% no due date | 27,491 | 27,955 | 0.3 | % | |||||||||||||
| mmTron Inc | Technology | Convertible Note, 4% due April 2023 | 100,000 | 101,030 | 0.9 | % | |||||||||||||
| Navaux Inc | Life science | Convertible Note, % due | 60,000 | 62,841 | 0.6 | % | |||||||||||||
| Neuro42 Inc. | Life science | Convertible Note, 8% due December 2023 | 50,000 | 52,564 | 0.5 | % | |||||||||||||
| Octagon Therapeutics Inc | Life science | Convertible Note, 5% due June 2021 | 50,000 | 52,349 | 0.5 | % | |||||||||||||
| Octagon Therapeutics Inc | Life science | Convertible Note, 5% due June 2021 | 50,000 | 52,219 | 0.5 | % | |||||||||||||
| Perikinetics Inc | Life science | Convertible Note, 6% due May 2022 | 100,000 | 105,326 | 1.0 | % | |||||||||||||
| Preview Medical Inc | Life science | Convertible Note, 7% due January 2023 | 100,000 | 104,948 | 1.0 | % | |||||||||||||
| Promaxo Inc | Life science | Convertible note, 5% due July 2022 | 100,000 | 183,876 | 1.7 | % | |||||||||||||
| Rheos Inc | Life science | Convertible note, 8% due August 2026 | 100,000 | 101,074 | 0.9 | % | |||||||||||||
| Saccharo Inc | Life science | Convertible note, 7% due September 2022 | 50,000 | 50,815 | 0.5 | % | |||||||||||||
| SageMedic Corp | Life science | Convertible Note, 8% April 2021 plus warrants | 50,000 | 59,885 | 0.6 | % | |||||||||||||
| SageMedic Corp | Life science | Convertible Note, 8% December 2022 plus warrants | 75,000 | 79,948 | 0.7 | % | |||||||||||||
| Sensing Electromagnetic Plus Corp | Technology | Convertible Note, Fully reserved | 50,000 | 1 | 0.0 | % | |||||||||||||
| Sensing Electromagnetic Plus Corp | Technology | Convertible Note, Fully reserved | 11,048 | 1 | 0.0 | % | |||||||||||||
| Single Pass Inc | Life science | Convertible Note, 6% April 2024 | 50,000 | 50,970 | 0.5 | % | |||||||||||||
| * | Valfix Medical Inc | * | Life science | Convertible Note, 8% December 2021 | 50,000 | 54,515 | 0.5 | % | |||||||||||
| * | Xpan Inc | * | Life science | Convertible Note, 8% due March 2022 | 50,000 | 56,301 | 0.5 | % | |||||||||||
| * | Xpan Inc | * | Life science | Convertible Note, 8% due June 2022 | 25,000 | 27,548 | 0.3 | % | |||||||||||
| * | Xpan Inc | * | Life science | Convertible Note, 8% due June 2022 | 25,000 | 27,542 | 0.3 | % | |||||||||||
| Total convertible loan investments | $ | 3,243,539 | $ | 3,801,833 | 35.1 | % | |||||||||||||
| United States | $ | 2,423,539 | $ | 2,873,150 | 26.6 | % | |||||||||||||
| Canada | 470,000 | 537,116 | 5.0 | % | |||||||||||||||
| Rest of World | 350,000 | 391,567 | 3.6 | % | |||||||||||||||
| Total convertible loan investments | $ | 3,243,539 | $ | 3,801,833 | 35.1 | % | |||||||||||||
Continued on next page
The accompanying notes are an integral part of these condensed interim financial statements.
| 8 |
Continued from previous page
Kyto Technology and Life Science, Inc.
Condensed Schedule of Investments as of September 30, 2021
(Unaudited)
| Portfolio Company | Industry | Investment | Cost | Fair value | % of net assets (a) | |||||||||||||
| Preferred stock investments | ||||||||||||||||||
| Altis Biosystems | Life science | shares of Series Seed Preferred | $ | 50,000 | $ | 50,000 | 0.5 | % | ||||||||||
| Astrocyte Pharmaceuticals Inc | Life science | shares of Series A Preferred | 100,000 | 100,000 | 0.9 | % | ||||||||||||
| Cnote Group, Inc | Fintech | shares of series Seed-2 Preferred (converted SAFE) | 51,500 | 59,783 | 0.6 | % | ||||||||||||
| Cnote Group, Inc | Fintech | shares of Series Seed-3 Preferred (converted note) | 50,000 | 66,247 | 0.6 | % | ||||||||||||
| Colabs Inc | Life science | shares of Series A-1 Preferred | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| * | Connectus Services Ltd | * | Technology | shares of Series Seed Preferred | 100,000 | 100,000 | 0.9 | % | ||||||||||
| Deep Blue Medical Advances Inc | Life science | shares of Series A Preferred | 49,996 | 49,997 | 0.5 | % | ||||||||||||
| Eumentis Thereapeutics Inc | Life science | shares of Series A Preferred | 100,000 | 100,000 | 0.9 | % | ||||||||||||
| FemtoDX Inc | Life science | shares of Series A Preferred | 100,000 | 290,046 | 2.7 | % | ||||||||||||
| Healionics Corporation | Life science | of Series A-1 Preferred | 100,000 | 100,000 | 0.9 | % | ||||||||||||
| i-Lumen Scientific Inc. | Life science | shares of Series A Preferred plus warrants | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| i-Lumen Scientific Inc. | Life science | shares of Series A Preferred plus warrants | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| Inhalon Biopharma Inc | Life science | shares of Series Seed Preferred | 99,997 | 99,997 | 0.9 | % | ||||||||||||
| Light Line Medical Inc | Life science | shares of Series Seed Preferred (converted note) | 30,000 | 38,031 | 0.4 | % | ||||||||||||
| Light Line Medical Inc | Life science | shares of Series Seed Preferred (converted note) | 70,000 | 106,049 | 1.0 | % | ||||||||||||
| Light Line Medical Inc | Life science | shares of Series Seed preferred | 25,000 | 25,000 | 0.2 | % | ||||||||||||
| Light Line Medical Inc | Life science | shares of Series A Preferred plus warrants | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| Lowell Therapeutics Inc | Life science | shares of Series A Preferred | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| Lowell Therapeutics Inc | Life science | shares of Series A Preferred | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| Lowell Therapeutics Inc | Life science | shares of Series B Preferred | 100,000 | 100,000 | 0.9 | % | ||||||||||||
| Makani Science Inc | Life science | shares of Series Seed Preferred | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| Micronic Technologies Inc | Technology | shares of Series Seed-1 Preferred plus warrants | 100,000 | 100,000 | 0.9 | % | ||||||||||||
| Neuroflow Inc | Life science | shares of Series Seed -2 Preferred | 150,000 | 224,998 | 2.1 | % | ||||||||||||
| Neuroflow Inc | Life science | shares of Series B Preferred | 100,000 | 212,497 | 2.0 | % | ||||||||||||
| New View Surgical, Inc. | Life science | shares of Series A-1 Preferred | 75,000 | 75,000 | 0.7 | % | ||||||||||||
| New View Surgical, Inc. | Life science | shares of Series A-1 Preferred | 100,000 | 100,000 | 0.9 | % | ||||||||||||
| * | Orion Biotechnology Inc | * | Life science | shares of Series A Preferred | 100,000 | 100,000 | 0.9 | % | ||||||||||
| Otomagnetics Inc | Life science | shares of Series A-1 Preferred | 100,000 | 100,000 | 0.9 | % | ||||||||||||
| Partheous Inc | Life science | shares of Series A Preferred | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| Promaxo | Life science | shares of Series B-1 Preferred, (converted note) | 250,000 | 1,034,684 | 9.6 | % | ||||||||||||
| Seal Rock Therapeutics, Inc. | Life science | shares of Series Seed Preferred, (converted note) | 78,000 | 199,112 | 1.8 | % | ||||||||||||
| Shyft (FKA Crater Group Inc) | Technology | shares of Series A-1 Preferred (converted note) | 51,500 | 107,059 | 1.0 | % | ||||||||||||
| Shyft (FKA Crater Group Inc) | Technology | shares of Series A Preferred (converted note) | 50,000 | 91,771 | 0.8 | % | ||||||||||||
| Shyft (FKA Crater Group Inc) | Technology | shares of Series A-1 Preferred (plus warrants) | 50,000 | 70,990 | 0.7 | % | ||||||||||||
| ( i ) | Trellis Bioscience LLC | Life science | shares of Series B Preferred plus warrants | 50,000 | 50,000 | 0.5 | % | |||||||||||
| ( i ) | Trellis Bioscience LLC | Life science | shares of Series B Preferred plus warrants | 50,000 | 50,000 | 0.5 | % | |||||||||||
| ( i ) | Trellis Bioscience LLC | Life science | shares of Series B Preferred plus warrants | 100,000 | 100,000 | 0.9 | % | |||||||||||
| * | Valfix Medical Inc | * | Life science | shares of Series Seed Preferred | 50,000 | 50,000 | 0.5 | % | ||||||||||
| Vesteck Inc | Life science | shares of Series A preferred | 100,000 | 100,000 | 0.9 | % | ||||||||||||
| Visgenx Inc | Life science | shares of Series Seed-1 Preferred (converted note) | 30,000 | 46,352 | 0.4 | % | ||||||||||||
| Visgenx Inc | Life science | shares of Series Seed Preferred (converted note) | 25,000 | 25,648 | 0.2 | % | ||||||||||||
| Visgenx Inc | Life science | shares of Series Seed Preferred (converted note) | 15,003 | 15,392 | 0.1 | % | ||||||||||||
| Total Preferred stock investments | $ | 3,050,997 | $ | 4,538,653 | 42.0 | % | ||||||||||||
| United States | $ | 2,800,997 | $ | 4,288,653 | 39.6 | % | ||||||||||||
| Canada | 200,000 | 200,000 | 1.8 | % | ||||||||||||||
| Rest of World | 50,000 | 50,000 | 0.5 | % | ||||||||||||||
| Total Preferred stock investments | $ | 3,050,997 | $ | 4,538,653 | 42.0 | % | ||||||||||||
| Common stock investments | ||||||||||||||||||
| * | BendaRX Corp | * | Life science | Common shares | $ | 100,000 | $ | 150,000 | 1.4 | % | ||||||||
| * | BendaRX Corp | * | Life science | Common shares | 100,000 | 150,000 | 1.4 | % | ||||||||||
| Boardwalk Tech | Technology | Common shares | 65,600 | 65,600 | 0.6 | % | ||||||||||||
| Boardwalk Tech | Technology | Common shares | 73,500 | 91,995 | 0.9 | % | ||||||||||||
| Kuantsol Inc | Technology | Common shares | 25,000 | 25,000 | 0.2 | % | ||||||||||||
| Sanaby Health Sponsor LLC | Life science | Common shares | 100,000 | 473,732 | 4.4 | % | ||||||||||||
| Total Common stock investments | $ | 464,100 | $ | 956,327 | 4.2 | % | ||||||||||||
| United States | $ | 264,100 | $ | 656,327 | 6.1 | % | ||||||||||||
| Canada |
| 200,000 | 300,000 | 2.8 | % | |||||||||||||
| Rest of World |
| - | - | |||||||||||||||
| Total Common stock investments | $ | 464,100 | $ | 956,327 | 8.8 | % | ||||||||||||
| * | ||||||||||||||||||
| SAFE investments | ||||||||||||||||||
| * | Infinidome Ltd | * | Technology | SAFE | $ | 50,000 | $ | 50,000 | 0.5 | % | ||||||||
| * | Infinidome Ltd | * | Technology | SAFE | 50,000 | 50,000 | 0.5 | % | ||||||||||
| * | Madorra Inc | * | Life science | SAFE | 100,000 | 100,000 | 0.9 | % | ||||||||||
| Mitre Medical Corp | Life science | SAFE | 75,000 | 75,000 | 0.7 | % | ||||||||||||
| Mitre Medical Corp | Life science | SAFE | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| * | Orion Biotechnology Inc. | * | Life science | SAFE | 100,000 | 100,000 | 0.9 | % | ||||||||||
| * | Polymertal Ltd | * | Technology | SAFE | 150,000 | 150,000 | 1.4 | % | ||||||||||
| Total SAFE investments | $ | 575,000 | $ | 575,000 | 5.3 | % | ||||||||||||
| United States | 125,000 | 125,000 | 1.2 | % | ||||||||||||||
| Canada | 100,000 | 100,000 | 0.9 | % | ||||||||||||||
| Rest of World | 350,000 | 350,000 | 3.2 | % | ||||||||||||||
| Total SAFE investments | $ | 575,000 | $ | 575,000 | 5.3 | % | ||||||||||||
Continued on next page
The accompanying notes are an integral part of these condensed interim financial statements.
| 9 |
Continued from previous page
Kyto Technology and Life Science, Inc.
Condensed Schedule of Investments as of September 30, 2021
(Unaudited)
| Portfolio Company | Industry | Investment | Cost | Fair value | % of net assets (a) | |||||||||||||
| Other investments | ||||||||||||||||||
| Enduralock LLC | Technology | Series A-1 Ownership Units | $ | 30,000 | $ | 30,000 | 0.3 | % | ||||||||||
| Enduralock LLC | Technology | Series A-1 Ownership Units | 35,000 | 35,000 | 0.3 | % | ||||||||||||
| ( i ) | Exodos Life Sciences LP | Life science | Class A-1 Preferred Ownership Units | 206,000 | 206,000 | 1.9 | % | |||||||||||
| Green Sun Medical LLC | Life science | Class A-1 Ownership units | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| Green Sun Medical LLC | Life science | Class A-1 Ownership units | 25,000 | 25,000 | 0.2 | % | ||||||||||||
| Green Sun Medical LLC | Life science | Class A-1 Ownership units | 25,000 | 25,000 | 0.2 | % | ||||||||||||
| Green Sun Medical LLC | Life science | Class A-1 Ownership units | 100,000 | 100,000 | 0.9 | % | ||||||||||||
| Riso Capital Fund I, LP | Technology | Ownership units | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| Riso Capital Fund I, LP | Technology | Ownership units | 50,000 | 50,000 | 0.5 | % | ||||||||||||
| Total other investments | $ | 571,000 | $ | 571,000 | 5.3 | % | ||||||||||||
| United States | $ | 571,000 | $ | 571,000 | 5.3 | % | ||||||||||||
| Canada | - | - | ||||||||||||||||
| Rest of World | - | - | ||||||||||||||||
| Total other investments | $ | 571,000 | $ | 571,000 | 5.3 | % | ||||||||||||
| Total investments | $ | 7,904,636 | $ | 10,442,813 | 96.5 | % | ||||||||||||
| United States | $ | 6,184,636 | $ | 8,514,130 | 78.7 | % | ||||||||||||
| Canada | 970,000 | 1,137,116 | 10.5 | % | ||||||||||||||
| Rest of World | 750,000 | 791,567 | 7.3 | % | ||||||||||||||
| Total investments | $ | 7,904,636 | $ | 10,442,813 | 96.5 | % | ||||||||||||
| (a) based on total net assets of | $ | 10,817,894 | ||||||||||||||||
( i ) Kyto representatives sit on the Board of Directors of these companies.
* These companies are headquartered outside of the US.
The accompanying notes are an integral part of these condensed interim financial statements.
| 10 |
Kyto Technology and Life Science, Inc.
Condensed Schedule of Investments as of March 31, 2021
(Unaudited)
| Portfolio Company | Industry | Investment | Cost | Fair value | % of net assets (a) | |||||||||||||||||||
| Convertible loan investments | ||||||||||||||||||||||||
| (i) | Achelios Therapeutics Inc. | Life science | Convertible Note, 8% due, December 2021 | $ | 100,000 | $ | 121,173 | 1.7 | % | |||||||||||||||
| (i) | Achelios Therapeutics Inc. | Life science | Convertible Note, 8% due December 2021 | 25,000 | 29,033 | 0.4 | % | |||||||||||||||||
| (i) | Achelios Therapeutics Inc. | Life science | Convertible Note, 8% due December 2021 | 50,000 | 54,581 | 0.8 | % | |||||||||||||||||
| Avisi Technologies Inc | Life science | Convertible Note, 8% due July 2022 | 50,000 | 52,674 | 0.8 | % | ||||||||||||||||||
| Basepaws Inc | Life science | Convertible Note, 1% due April 2020 | 50,000 | 162,319 | 2.3 | % | ||||||||||||||||||
| (i) | Beam Semiconductor Inc | * | Technology | Convertible Note, 8% due April 2022 | 150,000 | 171,041 | 2.4 | % | ||||||||||||||||
| (i) | Beam Semiconductor Inc | * | Technology | Convertible Note, 8% due March 2021 | 50,000 | 54,285 | 0.8 | % | ||||||||||||||||
| Corinnova Inc | Life science | Convertible Note, 6% due December 2024 | 100,000 | 102,318 | 1.5 | % | ||||||||||||||||||
| Cyberdontics Inc | * | Life science | Convertible Note, 8% due September 2022 | 30,000 | 33,768 | 0.5 | % | |||||||||||||||||
| Cyberdontics Inc | * | Life science | Convertible Note, 8% due February 2023 | 35,000 | 38,053 | 0.5 | % | |||||||||||||||||
| Cyberdontics Inc | * | Life science | Convertible Note, 0% no due date | 35,000 | 36,296 | 0.5 | % | |||||||||||||||||
| Deep Blue Medical Advances Inc | Life science | Convertible Note, 6% due June 2022 | 50,000 | 50,863 | 0.7 | % | ||||||||||||||||||
| Every Key Inc | Technology | Convertible Note, 5% due December 2023 | 100,000 | 106,521 | 1.5 | % | ||||||||||||||||||
| Identical Inc | Life science | Convertible Note, 2% due May 2022 | 100,000 | 100,844 | 1.4 | % | ||||||||||||||||||
| INBay Technology Inc | * | Technology | Convertible Note, 12% due October 2020 | 50,000 | 59,721 | 0.9 | % | |||||||||||||||||
| INBay Technology Inc | * | Technology | Convertible Note, 12% due July 2021 | 30,000 | 34,149 | 0.5 | % | |||||||||||||||||
| INBay Technology Inc | * | Technology | Convertible Note, 12% due February 2022 | 50,000 | 56,641 | 0.8 | % | |||||||||||||||||
| INBay Technology Inc | * | Technology | Convertible Note, 12% due December 2022 | 40,000 | 41,552 | 0.6 | % | |||||||||||||||||
| Kiana Analytics Inc | Technology | Convertible Note, 3% December 2022 | 100,000 | 100,847 | 1.4 | % | ||||||||||||||||||
| Kitotech Medical Inc | Life science | Convertible Note, 6% due December 2020 | 100,000 | 243,133 | 3.5 | % | ||||||||||||||||||
| Kitotech Medical Inc | Life science | Convertible Note, 6% due November 2022 | 75,000 | 83,738 | 1.2 | % | ||||||||||||||||||
| Lifewave Biomedical Inc | Life science | Convertible Note, 6% due December 2020 | 30,000 | 32,831 | 0.5 | % | ||||||||||||||||||
| Lifewave Biomedical Inc | Life science | Convertible Note, 6% due December 2020 | 70,000 | 74,810 | 1.1 | % | ||||||||||||||||||
| Navaux Inc | Life science | Convertible Note, % due | 60,000 | 61,036 | 0.9 | % | ||||||||||||||||||
| Neuro42 Inc. | Life science | Convertible Note, 8% due December 2023 | 50,000 | 50,559 | 0.7 | % | ||||||||||||||||||
| Octagon Therapeutics Inc | Life science | Convertible Note, 5% due June 2021 | 50,000 | 51,110 | 0.7 | % | ||||||||||||||||||
| Octagon Therapeutics Inc | Life science | Convertible Note, 5% due June 2021 | 50,000 | 50,966 | 0.7 | % | ||||||||||||||||||
| Perikinetics Inc | Life science | Convertible Note, 6% due May 2022 | 100,000 | 102,318 | 1.5 | % | ||||||||||||||||||
| Preview Medical Inc | Life science | Convertible Note, 7% due January 2023 | 100,000 | 101,918 | 1.5 | % | ||||||||||||||||||
| SageMedic Corp | Life science | Convertible Note, 8% April 2021 plus warrants | 50,000 | 57,879 | 0.8 | % | ||||||||||||||||||
| SageMedic Corp | Life science | Convertible Note, 8% December 2022 plus warrants | 75,000 | 77,088 | 1.1 | % | ||||||||||||||||||
| Sensing Electromagnetic Plus Corp | Technology | Convertible Note, Fully reserved | 50,000 | 1 | 0.0 | % | ||||||||||||||||||
| Sensing Electromagnetic Plus Corp | Technology | Convertible Note, Fully reserved | 11,048 | 1 | 0.0 | % | ||||||||||||||||||
| Valfix Medical Inc | * | Life science | Convertible Note, 8% December 2021 | 50,000 | 52,510 | 0.8 | % | |||||||||||||||||
| Xpan Inc | * | Life science | Convertible Note, 8% due March 2022 | 50,000 | 54,296 | 0.8 | % | |||||||||||||||||
| Xpan Inc | * | Life science | Convertible Note, 8% due June 2022 | 25,000 | 26,545 | 0.4 | % | |||||||||||||||||
| Xpan Inc | * | Life science | Convertible Note, 8% due June 2022 | 25,000 | 26,540 | 0.4 | % | |||||||||||||||||
| Total Convertible loan investments | $ | 2,216,048 | $ | 2,553,954 | 36.5 | % | ||||||||||||||||||
| United States | $ | 1,596,048 | $ | 1,868,557 | 26.7 | % | ||||||||||||||||||
| Canada | 370,000 | 407,561 | 5.8 | % | ||||||||||||||||||||
| Rest of World | 250,000 | 277,836 | 4.0 | % | ||||||||||||||||||||
| Total Convertible loan investments | $ | 2,216,048 | $ | 2,553,954 | 36.5 | % | ||||||||||||||||||
Continued on next page
The accompanying notes are an integral part of these condensed interim financial statements.
| 11 |
Continued from previous page
Kyto Technology and Life Science, Inc.
Condensed Schedule of Investments as of March 31, 2021 - continued
(Unaudited)
| Preferred stock investments | ||||||||||||||||||
| Altis Biosystems | Life science | shares of Series Seed Preferred | $ | 50,000 | $ | 50,000 | 0.7 | % | ||||||||||
| Astrocyte Pharmaceuticals Inc | Life science | shares of Series A Preferred | 100,000 | 100,000 | 1.4 | % | ||||||||||||
| Cnote Group, Inc | Fintech | shares of series Seed-2 Preferred (converted SAFE) | 51,500 | 59,783 | 0.9 | % | ||||||||||||
| Cnote Group, Inc | Fintech | shares of Series Seed-3 Preferred (converted note) | 50,000 | 66,247 | 0.9 | % | ||||||||||||
| Colabs Inc | Life science | shares of Series A-1 Preferred | 50,000 | 50,000 | 0.7 | % | ||||||||||||
| Connectus Services Ltd | * | Technology | shares of Series Seed Preferred | 100,000 | 100,000 | 1.4 | % | |||||||||||
| Deep Blue Medical Advances Inc | Life science | shares of Series A Preferred | 49,997 | 49,997 | 0.7 | % | ||||||||||||
| Eumentis Thereapeutics Inc | Life science | shares of Series A Preferred | 100,000 | 100,000 | 1.4 | % | ||||||||||||
| FemtoDX Inc | Life science | shares of Series A Preferred | 100,000 | 159,835 | 2.3 | % | ||||||||||||
| i-Lumen Scientific Inc. | Life science | shares of Series A Preferred plus warrants | 50,000 | 50,000 | 0.7 | % | ||||||||||||
| i-Lumen Scientific Inc. | Life science | shares of Series A Preferred plus warrants | 50,000 | 50,000 | 0.7 | % | ||||||||||||
| Inhalon Biopharma Inc | Life science | shares of Series Seed Preferred | 99,997 | 99,997 | 1.4 | % | ||||||||||||
| Light Line Medical Inc | Life science | shares of Series Seed Preferred (converted note) | 30,000 | 38,031 | 0.5 | % | ||||||||||||
| Light Line Medical Inc | Life science | shares of Series Seed Preferred (converted note) | 70,000 | 106,049 | 1.5 | % | ||||||||||||
| Light Line Medical Inc | Life science | shares of Series Seed preferred | 25,000 | 25,000 | 0.4 | % | ||||||||||||
| Light Line Medical Inc | Life science | shares of Series A Preferred plus warants | 50,000 | 50,000 | 0.7 | % | ||||||||||||
| Lowell Therapeutics Inc | Life science | shares of Series A Preferred | 50,000 | 50,000 | 0.7 | % | ||||||||||||
| Lowell Therapeutics Inc | Life science | shares of Series A Preferred | 50,000 | 50,000 | 0.7 | % | ||||||||||||
| Micronic Technologies Inc | Technology | shares of Series Seed-1 Preferred plus warrants | 100,000 | 100,000 | 1.4 | % | ||||||||||||
| Neuroflow Inc | Life science | shares of Series Seed -2 Preferred | 150,000 | 224,998 | 3.2 | % | ||||||||||||
| Neuroflow Inc | Life science | shares of Series B Preferred | 100,000 | 212,497 | 3.0 | % | ||||||||||||
| New View Surgical, Inc. | Life science | shares of Series A-1 Preferred | 75,000 | 75,000 | 1.1 | % | ||||||||||||
| Otomagnetics Inc | Life science | shares of Series A-1 Preferred plus warrants | 100,000 | 100,000 | 1.4 | % | ||||||||||||
| Promaxo | Life science | shares of Series B-1 Preferred, (converted note) | 250,000 | 531,738 | 7.6 | % | ||||||||||||
| Seal Rock Therapeutics, Inc. | Life science | shares of Series Seed Preferred, (converted note) | 78,000 | 80,329 | 1.1 | % | ||||||||||||
| Shyft (FKA Crater Group Inc) | Technology | shares of Series A-1 Preferred | 51,500 | 97,940 | 1.4 | % | ||||||||||||
| Shyft (FKA Crater Group Inc) | Technology | shares of Series A Preferred (converted note) | 50,000 | 64,626 | 0.9 | % | ||||||||||||
| Shyft (FKA Crater Group Inc) | Technology | shares of Series A-1 Preferred (converted note) | 50,000 | 50,000 | 0.7 | % | ||||||||||||
| (i) | Trellis Bioscience LLC | Life science | shares of Series B Preferred plus warrants | 50,000 | 50,000 | 0.7 | % | |||||||||||
| (i) | Trellis Bioscience LLC | Life science | shares of Series B Preferred plus warrants | 50,000 | 50,000 | 0.7 | % | |||||||||||
| (i) | Trellis Bioscience LLC | Life science | shares of Series B Preferred plus warrants | 100,000 | 100,000 | 1.4 | % | |||||||||||
| Valfix Medical Inc | * | Life science | shares of Series Seed Preferred | 50,000 | 50,000 | 0.7 | % | |||||||||||
| Visgenx Inc | Life science | shares of Series Seed-1 Preferred (converted note) | 30,000 | 46,352 | 0.7 | % | ||||||||||||
| Visgenx Inc | Life science | shares of Series Seed Preferred (converted note) | 25,000 | 25,648 | 0.4 | % | ||||||||||||
| Visgenx Inc | Life science | shares of Series Seed Preferred (converted note) | 15,003 | 15,392 | 0.2 | % | ||||||||||||
| Total Preferred stock investments | $ | 2,450,998 | $ | 3,129,458 | 44.8 | % | ||||||||||||
| United States | $ | 2,300,998 | $ | 2,979,458 | 42.6 | % | ||||||||||||
| Canada | 100,000 | 100,000 | 1.4 | % | ||||||||||||||
| Rest of World | 50,000 | 50,000 | 0.7 | % | ||||||||||||||
| Total Preferred stock investments | $ | 2,450,998 | $ | 3,129,458 | 44.8 | % | ||||||||||||
| Common stock investments | ||||||||||||||||||
| BendaRX Corp | * | Life science | Common shares | $ | 100,000 | $ | 150,000 | 2.1 | % | |||||||||
| BendaRX Corp | * | Life science | Common shares | 100,000 | 150,000 | 2.1 | % | |||||||||||
| Boardwalk Tech | Technology | Common shares | 73,500 | 91,995 | 1.3 | % | ||||||||||||
| Total common stock investments | $ | 273,500 | $ | 391,995 | 5.6 | % | ||||||||||||
| United States | $ | 73,500 | $ | 91,995 | 1.3 | % | ||||||||||||
| Canada | 200,000 | 300,000 | 4.3 | % | ||||||||||||||
| Rest of World | - | - | ||||||||||||||||
| Total common stock investments | $ | 273,500 | $ | 391,995 | 5.6 | % | ||||||||||||
| SAFE investments | ||||||||||||||||||
| Infinidome Ltd | * | Technology | SAFE | $ | 50,000 | $ | 50,000 | 0.7 | % | |||||||||
| Infinidome Ltd | * | Technology | SAFE | 50,000 | 50,000 | 0.7 | % | |||||||||||
| Mitre Medical Corp | Life science | SAFE | 75,000 | 75,000 | 1.1 | % | ||||||||||||
| Mitre Medical Corp | Life science | SAFE | 50,000 | 50,000 | 0.7 | % | ||||||||||||
| Orion Biotechnology Inc. | * | Life science | SAFE | 100,000 | 100,000 | 1.4 | % | |||||||||||
| Total SAFE investments | $ | 325,000 | $ | 325,000 | 4.6 | % | ||||||||||||
| United States | $ | 125,000 | $ | 125,000 | 1.8 | % | ||||||||||||
| Canada | 100,000 | 100,000 | 1.4 | % | ||||||||||||||
| Rest of World | 100,000 | 100,000 | 1.4 | % | ||||||||||||||
| Total SAFE investments | $ | 325,000 | $ | 325,000 | 4.6 | % | ||||||||||||
Continued on next page
The accompanying notes are an integral part of these condensed interim financial statements.
| 12 |
Continued from previous page
Kyto Technology and Life Science, Inc.
Condensed Schedule of Investments as of March 31, 2021 - continued
(Unaudited)
| Preferred stock investments | ||||||||||||||||||
| Other investments | ||||||||||||||||||
| Enduralock LLC | Technology | Series A-1 Ownership Units | $ | 30,000 | $ | 30,000 | 0.4 | % | ||||||||||
| Enduralock LLC | Technology | Series A-1 Ownership Units | 35,000 | 35,000 | 0.5 | % | ||||||||||||
| (i) | Exodos Life Sciences LP | Life science | Class A-1 Preferred Ownership Units | 206,000 | 206,000 | 2.9 | % | |||||||||||
| Green Sun Medical LLC | Life science | Class A-1 Ownership units | 50,000 | 50,000 | 0.7 | % | ||||||||||||
| Green Sun Medical LLC | Life science | Class A-1 Ownership units | 25,000 | 25,000 | 0.4 | % | ||||||||||||
| Green Sun Medical LLC | Life science | Class A-1 Ownership units | 25,000 | 25,000 | 0.4 | % | ||||||||||||
| Riso Capital Fund I, LP | Technology | Ownership units | 50,000 | 50,000 | 0.7 | % | ||||||||||||
| Total other investments | $ | 421,000 | $ | 421,000 | 6.0 | % | ||||||||||||
| United States | $ | 421,000 | $ | 421,000 | 6.0 | % | ||||||||||||
| Canada | - | - | ||||||||||||||||
| Rest of World | - | - | ||||||||||||||||
| Total Other investments | $ | 421,000 | $ | 421,000 | 6.0 | % | ||||||||||||
| Total investments | $ | 5,686,545 | $ | 6,821,407 | 97.5 | % | ||||||||||||
| United States | $ | 4,516,546 | $ | 5,486,011 | 78.4 | % | ||||||||||||
| Canada | 770,000 | 907,560 | 13.0 | % | ||||||||||||||
| Rest of World | 400,000 | 427,836 | 6.1 | % | ||||||||||||||
| Total investments | $ | 5,686,545 | $ | 6,821,407 | 97.5 | % | ||||||||||||
| (a) based on total net assets of | $ | 6,993,163 | ||||||||||||||||
| ( i ) | Kyto representatives sit on the Board of Directors of these companies. |
| * | These companies are headquartered outside of the US. |
| The accompanying notes are an integral part of these condensed interim financial statements. |
| 13 |
KYTO BIOPHARMA,TECHNOLOGY AND LIFE SCIENCE INC.
NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
September 30, 2021
NOTE 1 – DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION
Kyto Biopharma,Technology and Life Science, Inc. (the “Company”) was formed as a Florida corporation on March 5, 1999. On1999 under the name of B Twelve, Inc. In August, 14, 2002, the Company changed its name from B Twelve, Inc. to Kyto Biopharma,BioPharma Inc.
The Company was originally formed to acquire and develop innovative minimally toxic and non-immunosuppressive proprietary drugs for the treatment of cancer, arthritis, and other proliferateautoimmune diseases and autoimmune diseases.had been evaluating a number of strategies. As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior operations. In April 2018, the Board adopted a new business plan focused on the development of early-stage technology and life science businesses through early-stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, sophisticated early-stage investors and successful entrepreneurs with experience across a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. The Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally, it is expected that investments will be realized from an exit within a period of four to five years following initial investment. Such exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions or an initial public offering (“IPO”) which may result in cash or equity proceeds. Other than making its initial and, potentially, follow-on investments in its portfolio companies, the Company does not provide any financial support to any of its investees.
The Company has one regular employee – the CEO, Mr, Paul Russo. Prior to December 31, 2020, Mr. Russo was acting as a consultant to the Company and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged as an employee of the Company at a salary of $400,000 per annum of which 60% was paid monthly from January to April 2021, then 75% from May 2021, with the balance being deferred to be paid once the Company lists and starts trading on the Nasdaq exchange. The full terms of Mr. Russo’s employment are described in a Form 8-K filed on February 1, 2021, which was approved by the Compensation committee of the Board of Directors on that date. During the three months and six months ended September 30, 2021, Mr. Russo received gross pay of $90,000 and $170,000, respectively. No consulting fees and no options were granted to him during these periods. During the three months and six months ended September 30, 2020, Mr. Russo received 0payroll or consulting fees, however in the three and six months ended September 30, 2020 he received a bonus of $and was granted options to purchase shares of Common stock.
The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of the date of this filing, the Company had approximately $485,000 of cash to cover its operating expenses, and new investment requirements and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed interim financial statements have been prepared assuming the Company will continue to operate as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of its portfolio investment companies report delays in their programs.
| 14 |
At March 31, 2020, management determined that the Company was an investment company for purposes of Accounting Standards Codification Topic 946, Financial Services—Investment Companies (ASC Topic 946) disclosure, and adopted the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the SEC. KI is an internally managed, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As of the completion of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the merger, the Company had fewer than 100 non affiliated investors and filed under the 1934 Act relying on exemption Rule 3( c )(1).
As a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company is required to comply with additional regulatory requirements. The Company has prepared and submitted sequentially two N-2 Registration Statements to the SEC for review but has not yet received final approval of its registration as at the filing date of this report.
NOTE 2 - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
(A) BASIS OF PRESENTATION
The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, these unaudited condensed financial statements do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments (consisting only of normal recurring adjustments), which the Company considers necessary, for a fair presentation of those financial statements. The results of operations and cash flows for the three months and six months ended September 30, 2021 may not necessarily be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The condensed balance sheet as of March 31, 2021 was derived from the audited financial statements at that date, but does not include all the information and footnotes required by U.S. GAAP. The information contained in this Quarterly Report on Form 10-Q should be read in conjunction with the audited financial statements of the Company for the year ended March 31, 2021, included in the Annual Report on Form 10-K as filed with the Securities and Exchange Commission (the “SEC”) on August 10, 2021.
The Company’s condensed interim financial statements are prepared in accordance with U.S. GAAP, which requires the use of estimates, assumptions and the exercise of subjective judgment as to future uncertainties. Actual results could differ from those estimates, assumptions, and judgments. Significant items subject to such estimates will include determining the fair value of investments, revenue recognition, income tax uncertainties, stock-based compensation, and other contingencies.
The Company’s financial statements are prepared using the specialized accounting principles of ASC Topic 946. In accordance with this specialized accounting guidance, the Company recognizes and carries all of its investments at fair value with changes in fair value recognized in earnings. Additionally, the Company will not apply consolidation or equity method of accounting to its investments. The carrying amount of the Company’s financial instruments such as cash and payables approximates fair value due to the short maturity of such instruments. Net assets are calculated as the carrying amounts of assets, including the fair value of investments, less the carrying amounts of its liabilities.
| 15 |
(B) INVESTMENT TRANSACTIONS AND NET REALIZED AND UNREALIZED GAIN OR LOSS ON INVESTMENTS
The Company generates increases or decreases in its net assets from the sale of complete or partial investments following a merger or acquisition (“M&A”) transaction or restructuring or from the revaluation of portfolio company investments to recognize changes in their fair value, either upwards or downwards. As a minority early-stage investor, the Company does not have the ability to manage the timing or acceptance of liquidity events that will realize its investments, nor the ability to predict when they may happen, although as a general guideline, it would expect such events to occur approximately four to five years after its investments are made. The Company records the realized gains and losses from investment activities upon completion of sale and receipt of net proceeds, after deducting related transaction expenses. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized. The Company is currentlyin periodic contact with the management of its portfolio investment companies to provide a basis for valuation changes. The Company does not expect to receive interest and principal repayments on its convertible notes and generally expects these notes to convert into equity securities upon completion of qualified subsequent financings. Accrued interest is recorded as an adjustment to the fair value of the convertible notes.
(C) INCOME TAXES
The Company accounts for income taxes under the Financial Accounting Standards Accounting Standard Codification Topic 740 “Accounting for Income Taxes” (“Topic 740”). Under Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the development stage as ityears in which those temporary differences are expected to be recovered or settled. Under Topic 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the process of looking at a number of strategies to become active. Once it has settled onperiod, which includes the strategy, the Company will develop a plan for an acquisition and the means to achieve its goal.
(D) USE OF ESTIMATES
In preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period presented. Actual results may differ from these estimates.
Significant estimates during 2017the three months and six months ended September 30, 2021 and September 30, 2020 include the valuation allowance of the investment portfolio, deferred tax assets.
(E) CASH AND CASH EQUIVALENTS
The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. There were no0 cash equivalents at December 31, 2017September 30, 2021 and March 31, 2017,2021, respectively.
(F) CONCENTRATIONS
The Company maintains its cash in bank checking and deposit accounts, which, at times, may exceed federally insured limits. As of DecemberSeptember 30, 2021, and March 31, 2017,2021, the Company did not have any deposits in excess ofCompany’s bank balance exceeded the federally insured limits.limit by approximately $70,000 and $1.2 million, respectively. The Company has not experienced any losses in such accounts through December 31, 2017September 30, 2021.
| 16 |
(G) STOCK-BASED COMPENSATION
Financial Accounting Standards Board Accounting Standards Codification Topic 718, “Stock Compensation” requires generally that all equity awards granted to employees and March 31, 2017, respectively.
In accordance with Statement of Financial Accounting Standards Accounting Standard Codification Topic 260, "Earnings“Earnings per Share"Share”, basic earnings per common share is computed by dividing the net income less preferred dividends for the period by the weighted average number of common shares outstanding. Diluted earnings per common share is computed by dividing net income less preferred dividends by the weighted average number of common shares outstanding including the effect of common stock equivalents. Common stock equivalents consisting of preferred stock, stock options and warrants, have not been includedwarrants. The following table sets out the number of shares used in calculating fully- diluted earnings per common share using the if-converted method.
Weighted Average method
SCHEDULE OF EARNINGS PER SHARE
Three months | Six months | |||||||
| Common Stock | 13,271,996 | 13,269,764 | ||||||
| Common stock subscribed not issued | - | - | ||||||
| Series A preferred stock | 4,200,000 | 4,200,000 | ||||||
| Series B preferred stock | 5,307,240 | 4,361,525 | ||||||
| Options | 2,962,792 | 2,835,262 | ||||||
| Warrants | 1,596,667 | 1,596,667 | ||||||
| Total shares used in calculating fully-diluted earnings per common share | 27,338,695 | 26,263,218 | ||||||
| Three months ended September 30, 2020 | Six months | |||||||
| Common Stock issued | 5,836,832 | 5,836,832 | ||||||
| Series A preferred stock | 4,200,000 | 4,200,000 | ||||||
| Series B preferred stock | 1,830,208 | 1,250,595 | ||||||
| Options | 1,920,000 | 1,571,429 | ||||||
| Warrants | 4,200,000 | 4,200,000 | ||||||
| Total shares used in calculating fully-diluted earnings per common share | 17,987,040 | 17,058,856 | ||||||
| 17 |
(I ) INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE
The Company reviews the performance of its investments based on available information, including management reports, press releases, web site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports, to determine their fair values. In the event that management considers the fair value of an investment to be greater or less than the current book value, the difference will be reflected as unrealized gains or losses in investments in the calculation,statements of operations.
The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing U.S. GAAP that require the use of fair value measurements which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.
Fair value is defined as their effectthe price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is anti-dilutivean exchange price notion under which fair value is the price in an orderly transaction between market participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the periods presented.
The accompanying unaudited condensedCompany has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed and approved. The Company uses observable market data to estimate the fair value of investments to the extent that market data is available. In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active, the Company uses the valuation methodologies described below with unobservable data based on the best available information in the circumstances, which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.
For investments for which quoted market prices are not available, which comprise most of our investment portfolio, fair value is estimated by using the income, market, or back-solve approach. The income approach is based on the assumption that value is created by the expectation of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive those future benefits. The market approach compares recent comparable transactions to the investment. The back solve method involves comparing available data over a period of time and inferring a new valuation based on changes from a known starting point, for example the cost of an investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These valuation methodologies involve a significant degree of judgment on the part of our management and board.
In determining the appropriate fair value of an investment using these approaches, the most significant information and assumptions may include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral, the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business, comparisons of financial statementsratios of Kyto Biopharma, Inc. (the "Company")peer companies that are public, merger and acquisition comparables, the principal market and enterprise values, environmental factors, subsequent financings by the portfolio investment, among other factors.
The estimated fair values do not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments, the estimate of fair values may differ significantly from the value that would have been prepared pursuantused had a broader market for the investments existed.
The authoritative accounting guidance prioritizes the use of market-based inputs over entity-specific inputs and establishes a three-level hierarchy for fair value measurements based upon the transparency of inputs to the rules and regulationsvaluation. The three levels of valuation hierarchy are defined as follows:
Level 1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data
Level 3: Unobservable inputs for which there is little or no market data, which require the use of the Securitiesreporting entity’s own assumptions. Most of the Company’s investments are Level 3.
| 18 |
Critical accounting policies and Exchange Commission (the "SEC”). Certain informationpractices are the policies that are both most important to the portrayal of the Company’s financial condition and footnote disclosures, normally included in financial statements prepared in accordance with accounting principles generally accepted inresults, and require management’s most difficult, subjective, or complex judgments, often as a result of the United States of America have been condensed or omitted pursuant to such SEC rules and regulations. Nevertheless, the Company believes that the disclosures are adequateneed to make the information presented not misleading.estimates about matters that are inherently uncertain. These interim unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company's March 31, 2017 Annual Report as filed on Form 10K. In the opinion of management, all adjustments, including normal recurring adjustments necessary to present fairly the financial positioninclude estimates of the Company with respect tofair value of Level 3 investments and other estimates that affect the interim unaudited condensedreported amounts of assets and liabilities as of the date of the consolidated financial statements and the resultsreported amounts of its operations forcertain revenues and expenses during the interim period ended December 31, 2017, have been included. The results of operations for interim periods are not necessarily indicative of the results for a full year.
(J) RECENT ACCOUNTING STANDARDS UPDATES
Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited condensed financial statements.
(K) OTHER CURRENT ASSETS
Other current assets principally include deferred offering costs. Since April 2019, the Company has conducted a series of sales of common and preferred stock to fund its ongoing investment program and cost of operations. Typically, it expects that raising capital through the sale of any series of securities, from start to finish, may take from six to nine months ended December 31, 2017,and in order to match the cost and benefits of this process, the Company receivedadopted a net loan from a related partypolicy of capitalizing direct expenses incurred in the amountcourse of $20,960.raising capital, with the intention of netting accumulated expenses against proceeds from sale of equity, and reporting the net funds raised at the close. Direct expenses include legal fees, investor relations fees, investor roadshows and meeting expenses, and related filing and printing fees. At December 31, 2017September 30, 2021 and March 31, 2017,2021, the Company had deferred $230,434 and $169,891, respectively, of such expenses, relating to the preparation and filing of an N-2 Registration Statement.
NOTE 3 – COMMITMENTS AND CONTINGENCIES
The Company has no commitments or contingencies as of the date of this filing. The Company may be subject to litigation during the normal course of business but has not received any such claims to date.
NOTE 4 - RELATED PARTY TRANSACTIONS
At September 30, 2021 and March 31, 2021, the Company had accrued and owed $89,067$87,000 and $68,107,$51,420, respectively, to a related partyofficers of the Company. Company for deferred payroll and consulting service fees.
At September 30, 2021, officers or directors of the Company held board positions at four portfolio companies: Beam Semiconductor Inc., Trellis Bioscience Inc., Exodos Life Sciences LP, and Achelios Therapeutics Inc.
| 19 |
NOTE 5 – INVESTMENTS
The loansfollowing table summarizes the Company’s investment portfolio at September 30, 2021 and March 31, 2021.
SUMMARY OF INVESTMENT PORTFOLIO
| September 30, 2021 | March 31, 2021 | |||||||||||||||
| Number of portfolio companies | 66 | 51 | ||||||||||||||
| Fair value | $ | 10,442,813 | $ | 6,821,407 | ||||||||||||
| Cost | 7,904,636 | 5,686,545 | ||||||||||||||
| % of portfolio at fair value | ||||||||||||||||
| Convertible notes | 3,801,833 | 36.4 | % | 2,553,954 | 37.4 | % | ||||||||||
| Preferrred stock | 4,538,653 | 43.5 | % | 3,129,458 | 45.9 | % | ||||||||||
| Common stock | 956,327 | 9.2 | % | 391,995 | 5.7 | % | ||||||||||
| SAFE | 575,000 | 5.5 | % | 325,000 | 4.8 | % | ||||||||||
| Other ownership units | 571,000 | 5.5 | % | 421,000 | 6.2 | % | ||||||||||
| Total | $ | 10,442,813 | 100 | % | $ | 6,821,407 | 100 | % | ||||||||
A SAFE is a Simple Agreement for Future Equity in the form of a warrant to purchase equity stock in a future priced round.
Our investment portfolio represents approximately 96% of our net assets at September 30, 2021 and 98% at March 31, 2021. Investments in early-stage start-up private operating entities are non-interest bearing, unsecuredvalued based on available metrics, such as relevant market multiples and duecomparable company valuations, company specific-financial data including subsequent financings, actual and projected results, and independent third-party valuation estimates.
Significant Unobservable Inputs for Level 3 Assets and Liabilities
In accordance with FASB ASC 820, Fair Value Management, the tables below provide quantitative information about the Company’s fair value measurements of its Level 3 assets as of September 30, 2021 and March 31, 2021. In addition to the techniques and inputs noted in the tables above, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not meant to be all-inclusive, but rather provide information on demand. the significant Level 3 inputs as they relate to the Company’s fair value measurements. To the extent an unobservable input is not reflected in the tables below, such input is deemed insignificant with respect to the Company’s Level 3 fair value measurements. Significant changes in the inputs in isolation would result in a significant change in the fair value measurement, depending on the materiality of the investment.
| 20 |
The loansfollowing table summarizes the valuation techniques and significant unobservable inputs used for investments that are categorized within Level 3 of the fair value hierarchy as of September 30, 2021 and March 31, 2021:
SCHEDULE OF INVESTMENTS
| As of September 30, 2021 | ||||||||||
| Fair Value | Valuation Approach/ Technique | Unobservable Inputs | Range/ Weighted Average | |||||||
| Convertible notes: Basepaws Inc | $ | 201,663 | Market approach based on indicative term sheet and last round of financing | As if converted note and Series A term sheet of $37.5 million | 50:50 weight | |||||
| Convertible notes: Promaxo Inc | 183,876 | Market approach based on available comparables and financial performance | Conversion prospects, market yield, remaining maturity | 5% yield | ||||||
| Convertible notes: Other | 3,416,294 | Market approach based on available comparables and financial performance | Conversion prospects, market yield, remaining maturity | 1-12% yield | ||||||
| Preferred stock in private companies” Shyft Moving Inc | 269,820 | Market approach based on indicative term sheet and last round of financing | 50/50 weighting to prior A-3 preferred and indicated pre Series B price. Forecast revenue from investor deck and 75% percentile for public company peer valuation ratios | Based on Series B valuation of $80 million | ||||||
| Preferred stock in private companies: Seal Rock Therapeutics Inc | 199,112 | Market approach based on indicative term sheet and last round of financing | 50/50 weighting to prior Series seed preferred and indicated Note price. 75% percentile for public company peer valuation ratios | Based on new Note indication of $80 million | ||||||
| Preferred stock in private companies: Femto DX Inc | 290,046 | Market approach based on indicative term sheet and last round of financing | 50/50 weighting to prior Series B-2 preferred price and public market. 75% percentile for public company peer valuation ratios | Based on Series B valuation of $170 million | ||||||
| Preferred stock in private companies: Promaxo Inc | 1,034,984 | Market approach based on available comparables and financial performance | a) Last round of financing for series B-2 price, 118% change in enterprise value @75th percentile b) revenue multiples 2021 13.3X 2022 9.3x | 0%-168.3% 0.6x - 27.7x 0.5x - 59.4x | ||||||
| Preferred stock in private companies: Other | 2,744,691 | Market approach based on available comparables and financial performance | Market approach based on available information from portfolio companies | Various | ||||||
| Common stock in private companies | 325,000 | Market approach based on available comparables and financial performance | Historic or projected revenue and/or EBITDA multiples discounted for lack of marketability | Various | ||||||
| SAFE | 575,000 | Market approach based on available comparables and financial performance | Precedent and follow-on transactions adjusted for marketability | Various | ||||||
| Other investments | 571,000 | Market approach based on available comparables and financial performance | Precedent and follow-on transactions adjusted for marketability | Various | ||||||
| Total Investments | $ | 9,811,486 | ||||||||
| As of March 31, 2021 | ||||||||||
| Fair Value | Valuation Approach/ Technique | Unobservable Inputs | Range/ Weighted Average | |||||||
| Convertible notes: Kitotech Medical Inc | $ | 326,871 | Market approach based on available comparables and financial performance | Market cap of $28.51 million a, Public company 75th percentile As if converted 2020 note | Range : $28.514 million | |||||
| Convertible notes | 2,227,083 | Market approach based on available comparables and financial performance | Conversion prospects, market yield, remaining maturity | 1-12% yield | ||||||
| Preferred stock in private companies: Femto DX Inc | 159,835 | Market approach based on available comparables and financial performance | Based on Series B financing and public company peer multiples using 50:50 percentile | Market value of invested capital $58.66 million | ||||||
| Preferred stock in private companies: Neuroflow Inc | 437,495 | Market approach based on available comparables and financial performance | Based on Series Seed 2 and last round of financing - Series B | Market value of invested capital $57.98 million | ||||||
| Preferred stock in private companies: other | 2,532,128 | Market approach based on available comparables and financial performance | Market approach based on available information from portfolio companies | Various | ||||||
| Common stock in private companies | 300,000 | Market approach based on available comparables and financial performance | Historic or projected revenue and/or EBITDA multiples | Various | ||||||
| SAFE | 325,000 | Market approach based on available comparables and financial performance | Precedent and follow-on transactions adjusted for marketability | Various | ||||||
| Other investments | 421,000 | Market approach based on available comparables and financial performance | Precedent and follow-on transactions adjusted for marketability | Various | ||||||
| Total Investments | $ | 6,729,412 | ||||||||
| 21 |
The following table presents fair value measurements of investments, by major class, as of September 30, 2021, and March 31, 2021, according to the fair value hierarchy:
SCHEDULE OF INVESTMENTS AT FAIR VALUE MEASUREMENTS OF INVESTMENTS
| As of September 30, 2021 | ||||||||||||||||
| Quoted prices in active markets for identical securities | Significant other observable inputs | Significant unobservable inputs | ||||||||||||||
| Description | (Level 1) | (Level 2) | (Level 3) | Total | ||||||||||||
| Investments at Fair Value | ||||||||||||||||
| Private Portfolio Companies | ||||||||||||||||
| Convertible notes | $ | - | $ | - | $ | 3,801,833 | $ | 3,801,833 | ||||||||
| Preferred stock | - | - | 4,538,653 | 4,538,653 | ||||||||||||
| Common stock | - | - | 325,000 | 325,000 | ||||||||||||
| SAFEs | - | - | 575,000 | 575,000 | ||||||||||||
| Other ownership interests | - | - | 571,000 | 571,000 | ||||||||||||
| - | - | 9,811,486 | 9,811,486 | |||||||||||||
| Public Portfolio Companies | ||||||||||||||||
| Common stock | 631,327 | - | - | 631,327 | ||||||||||||
| Total Investments at Fair value | $ | 631,327 | $ | - | $ | 9,811,486 | $ | 10,442,813 | ||||||||
| As of March 31, 2021 | ||||||||||||||||
| Description | Level 1 | Level 2 | Level 3 | Total | ||||||||||||
| March 31, 2021 | ||||||||||||||||
| Investments at Fair Value | ||||||||||||||||
| Private Portfolio Companies | ||||||||||||||||
| Convertible notes | $ | - | $ | - | $ | 2,553,954 | $ | 2,553,954 | ||||||||
| Preferred stock | - | - | 3,129,458 | 3,129,458 | ||||||||||||
| Common stock | - | - | 300,000 | 300,000 | ||||||||||||
| SAFEs | - | - | 325,000 | 325,000 | ||||||||||||
| Other ownership interests | - | - | 421,000 | 421,000 | ||||||||||||
| - | - | 6,729,412 | 6,729,412 | |||||||||||||
| Public Portfolio Companies | ||||||||||||||||
| Common stock | 91,995 | - | - | 91,995 | ||||||||||||
| Total Investments at Fair value | $ | 91,995 | $ | - | $ | 6,729,412 | $ | 6,821,407 | ||||||||
As of September 30, 2021, and March 31, 2021, all our investments were treated as Level 3 with the exception of two which are invested in common stock of a public company and treated as Level 1.
We focus on making our investments in the United States, Canada, and Israel. All investments are made and reported in U.S. dollars. Assets that are denominated in foreign currencies are translated into U.S. dollars at closing rates of exchange on the date of valuation. Transactions during the year are translated at the rate of exchange prevailing on the date of the transaction. The Company does not isolate that portion of results of operations resulting from the changes in foreign exchange rates on securities from fluctuations resulting from changes in market prices of such securities. Such foreign currency translation gains and losses are included in loans payable, related partythe net realized gains or losses from investments and net changes in unrealized gain or losses from investments on the accompanying balance sheet.statement of operations.
| 22 |
SCHEDULE OF INVESTMENTS IN UNREALIZED GAIN OR LOSSES FOREIGN EXCHANGE RATES ON SECURITIES
| America | Canada | Rest of World | Total | |||||||||||||
| Fair value beginning of year March 31, 2021 | $ | 5,486,011 | $ | 907,560 | $ | 427,836 | $ | 6,821,407 | ||||||||
| New investments | 1,668,091 | 200,000 | 350,000 | 2,218,091 | ||||||||||||
| Proceeds from sale of investments | - | - | - | - | ||||||||||||
| Realized gains | - | - | - | - | ||||||||||||
| Net change in unrealized gains included in condensed Statements of Operations | 1,360,028 | 29,556 | 13,731 | 1,403,315 | ||||||||||||
| Fair value end of six months September 30, 2021 | $ | 8,514,130 | $ | 1,137,116 | $ | 791,567 | $ | 10,442,813 | ||||||||
| Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | $ | 1,403,315 | ||||||||||||||
| America | Canada | Rest of World | Total | |||||||||||||
| Fair value beginning of year March 31, 2020 | $ | 2,170,499 | $ | 245,000 | $ | 250,000 | $ | 2,665,499 | ||||||||
| New investments | 540,000 | 150,000 | 50,000 | 740,000 | ||||||||||||
| Proceeds from sale of investments | - | - | - | - | ||||||||||||
| Realized gains | - | - | - | - | ||||||||||||
| Net change in unrealized gains included in condensed Statements of Operations | 438,953 | 21,947 | 17,348 | 478,248 | ||||||||||||
| Fair value end of six months September 30, 2020 | $ | 3,149,452 | $ | 416,947 | $ | 317,348 | $ | 3,883,747 | ||||||||
| Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | $ | 478,248 | ||||||||||||||
Working on the experience of our technical advisors, we limit our investments to fintech, technology, and life sciences.
| Fintech | Technology | Life science | Total | |||||||||||||
| Fair value beginning of year March 31, 2021 | $ | 126,030 | $ | 1,394,318 | $ | 5,301,059 | $ | 6,821,407 | ||||||||
| New investments | - | 590,600 | 1,627,491 | 2,218,091 | ||||||||||||
| Proceeds from sale of investments | - | - | - | - | ||||||||||||
| Realized gains | - | - | - | - | ||||||||||||
| Net change in unrealized gains included in condensed Statements of Operations | - | 45,531 | 1,357,784 | 1,403,315 | ||||||||||||
| Fair value end of six months September 30, 2021 | $ | 126,030 | $ | 2,030,449 | $ | 8,286,334 | $ | 10,442,813 | ||||||||
| Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | $ | 1,403,315 | ||||||||||||||
| Fintech | Technology | Life science | Total | |||||||||||||
| Fair value beginning of year March 31, 2020 | $ | 101,500 | $ | 685,002 | $ | 1,878,997 | $ | 2,665,499 | ||||||||
| New investments | - | - | 740,000 | 740,000 | ||||||||||||
| Proceeds from sale of investments | - | - | - | - | ||||||||||||
| Realized gains | - | - | - | - | ||||||||||||
| Net change in unrealized gains included in condensed Statements of Operations | 24,530 | 37,769 | 415,949 | 478,248 | ||||||||||||
| Fair value end of six months September 30, 2020 | $ | 126,030 | $ | 722,771 | $ | 3,034,946 | $ | 3,883,747 | ||||||||
| Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | $ | 478,248 | ||||||||||||||
| 23 |
We invest in early-stage private companies developing products or solutions in the fields of fintech, technology and life sciences. Typically, we are investing in interest bearing notes that may be convertible into equity securities upon the completion of qualified subsequent financings, preferred stock, SAFEs or other forms of ownership. Typically notes carry a two-year term and are then rolled over for additional periods if no other maturity triggers have been achieved. If a convertible note investment were, in our judgment, to become impaired, we would reverse the accrued interest and adjust the valuation to reflect management’s assessment of fair value. If a convertible note investment exceeds its maturity date we would request the portfolio company to document an extension, as well as consider whether the overdue note, along with all other available performance data and management reviews lead us to consider whether there should be an adjustment in fair value of the investment. There were no transfers into or out of Level 3 during the three and six months ended September 30, 2021 and September 30, 2020.
SCHEDULE OF ADJUSTMENT IN FAIR VALUE TO REFLECT IMPAIRMENT OF INVESTMENT
| Convertible notes | Preferred stock | Common stock | SAFEs | Other ownership interests | Total | |||||||||||||||||||
| Fair value March 31, 2021 | $ | 2,553,954 | $ | 3,129,458 | $ | 391,995 | $ | 325,000 | $ | 421,000 | $ | 6,821,407 | ||||||||||||
| Conversions into preferred stock | - | - | - | - | - | - | ||||||||||||||||||
| New investments | 1,027,491 | 600,000 | 190,600 | 250,000 | 150,000 | 2,218,091 | ||||||||||||||||||
| Proceeds from sale of investments | - | - | - | - | - | - | ||||||||||||||||||
| Realized gains | - | - | - | - | - | - | ||||||||||||||||||
| Unrealized gains included in condensed Statements of Operations | 220,388 | 809,195 | 373,732 | - | - | 1,403,315 | ||||||||||||||||||
| Fair value September 30, 2021 | $ | 3,801,833 | $ | 4,538,653 | $ | 956,327 | $ | 575,000 | $ | 571,000 | $ | 10,442,813 | ||||||||||||
| Convertible notes | Preferred stock | Common stock | SAFEs | Other ownership interests | Total | |||||||||||||||||||
| Fair value March 31, 2020 | $ | 1,528,002 | $ | 701,497 | $ | 126,500 | $ | 73,500 | $ | 236,000 | $ | 2,665,499 | ||||||||||||
| Conversions into preferred stock | (597,984 | ) | 678,313 | - | (80,329 | ) | - | - | ||||||||||||||||
| New investments | 100,000 | 440,000 | 100,000 | - | 100,000 | 740,000 | ||||||||||||||||||
| Proceeds from sale of investments | - | - | - | - | - | - | ||||||||||||||||||
| Realized gains | - | - | - | - | - | - | ||||||||||||||||||
| Unrealized gains included in condensed Statements of Operations | 178,986 | 279,433 | (62,000 | ) | 81,829 | - | 478,248 | |||||||||||||||||
| Fair value September 30, 2020 | $ | 1,209,004 | $ | 2,099,243 | $ | 164,500 | $ | 75,000 | $ | 336,000 | $ | 3,883,747 | ||||||||||||
NOTE 6– EQUITY
| (A) | PREFERRED STOCK |
Series A
The Company leases office spacehas sold Series A Stock Units (“Units”) consisting of one share of Series A Preferred Stock and administrative services fromone warrant to purchase a related party principal stockholder. Rentshare of Common Stock at $ per share. The Units were sold in a private placement to accredited investors. The Series A Preferred Stock will be converted into shares of Common Stock upon listing of the Company on Nasdaq or NYSE. In the event of any liquidation or winding up of the Company, the holders of the Series A shall be entitled to receive in preference to the holders of shares of Common Stock a per share amount equal to two times (2 X) their original purchase price plus any declared but unpaid dividends (the Liquidation Preference). All share issuances and administrative expenseobligations are recognized on the books and stock register.
On March 2, 2021, in preparation for an intended IPO, the Company made an offer to all its preferred shareholders to protect them against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Series A-1 and Series A-2 Preferred Stock were created, and the holders of Series A Preferred Stock were granted an opportunity to purchase shares of Common Stock at $ per share. If shareholders purchased at least $6,000 of Common Stock, their shares of Series A Preferred Stock were exchanged for Series A-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if shareholders purchased a pro-rated amount of Common Stock their Series A Preferred Stock were exchanged for Series A-2 Preferred Stock which in turn is convertible into shares of Common Stock at a discount of % to the IPO price. In all other respects the Series A-1 and Series A-2 Preferred Stock has the same rights and obligations as the Series A Preferred Stock. As of September 30, 2021, shares of Series A Preferred Stock had been exchanged for Series A-1 Preferred Stock, and shares of Series A Preferred Stock had been exchanged for Series A-2 Preferred Stock, respectively, leaving outstanding shares of Series A Preferred Stock (“Series A”) designated at a par value of $ per share.
| 24 |
Series B
There were also shares of Series B Preferred Stock (“Series B”) authorized designated at a par value of $ per share. The Series B can be converted into shares of Common Stock upon listing of the Company on Nasdaq. In the event of any liquidation or winding up of the Company, the holders of the Series B shall be entitled to receive in preference to the holders of Common Shares and Series A Preferred Stock, a per share amount equal to two times (2 X) their original purchase price plus any declared but unpaid dividends (the Liquidation Preference). The holders of Series B shall be entitled to receive out of any funds of the Corporation at a time legally available for the ninedeclaration of dividends, dividends at a cumulative rate of 10% under such terms and conditions as the Board shall prescribe, provided, however, that in the event dividends shall be declared, dividends on issued and outstanding Series B shall be payable before any dividends shall be declared or paid upon or set apart for the Common Stock.
On March 2, 2021, in preparation for an intended future IPO, the Company made an offer to all its preferred shareholders to protect them against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Series B-1 and Series B-2 Preferred Stock (“Series B-1” and “Series B-2”, respectively) were created, and the holders of the Series B were granted an opportunity to purchase shares of Common Stock at $ per share. If shareholders purchased at least $6,000 of Common Stock, their Series B were exchanged for Series B-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if shareholders purchased a pro-rated amount of Common Stock their Series B were exchanged for Series B-2 which converts into shares of Common Stock at a discount of % to the IPO price. In all other respects, the Series B-1 and Series B-2 have the same rights and obligations as the Series B. At September 30, 2021, shares of Series B had been exchanged for Series B-1, and shares of Series B had been exchanged for Series B-2, respectively, leaving outstanding shares of Series B. During the three and six months ended December 31, 2017September 30, 2021, the Company sold and 2016 was $30,000 shares of Series B-1 Preferred Stock for $1,273,000 and $30,000, respectively and is included in general and administrative expense in the accompanying statements of operations.
As of December 31, 2017September 30, 2021, the Company authorized an additional shares of Series B stock designated as Series B-3 Preferred (“Series B-3”) bringing Series B to a total of authorized shares with a par value of $ per share. The Certificate of Designation of the Series B-3 shares was filed with the Delaware Secretary of State on October 5, 2021. The Series B-3 will be offered for $ per share and accrue a cumulative dividend of % per annum. The remaining terms and conditions are substantially the same as for all other Series B shares, including mandatory conversion upon a majority vote of the Series B-3 shareholders, closing of a qualified financing of at least $10 million, or listing on a public stock exchange.
B) COMMON STOCK
The Company has authorized shares of common stock at a par value of $ per share. As of September 30, 2021, and March 31, 2017, the remaining balance in the accrued liabilities-related party account for the above services was $196,0002021 a total of and $148,000, respectively.
During the three and six months ended September 30, 2021, in connection with the amendment of Preferred Stock rights described in A above, the Company sold shares of Common Stock for $1,314,317 of which $ was received and accrued as subscription liability at March 31, 2021.
During each of the three and six months ended September 30, 2021, the Company issued shares of Common Stock for $618, respectively, in connection with the exercise of stock options.
| 25 |
C) STOCK OPTIONS
In April 2018, the Board approved the introduction of the Kyto Technology and Life Science, Inc. Incentive Stock Option Plan (“the 2018 Plan”) reserving shares for issuance to employees, consultants and directors, with the objective of securing the benefit of services for stock options rather than cash salaries.
In July 2019, the Board approved the introduction of the Kyto Technology and Life Science 2019 Stock Option and Incentive Plan (“2019 Plan”), and reserved million shares for issuance to directors, officers, consultants and advisors. Options granted under the 2019 Plan expire .
In December 2020, the Board approved the introduction of the Kyto Technology and Life Science 2020 Non Qualified Stock Option Plan (“2020 Plan”), and reserved million shares for issuance to directors, officers, consultants and advisors. Options granted under the 2020 Plan expire December 16, 2030.
During the three months ended September 30, 2021, and September 30, 2020, the Company issued a total of and non-qualified stock options, respectively, to consultants and advisors vesting over terms of . During the corresponding six months ended September 30, 2021, and September 30, 2020, the Company issued a total of and non-qualified stock options, respectively.
| Number of options granted | Weighted average exercise price | Weighted average remaining life years | ||||||||||
| Outstanding March 31, 2021 | 2,634,250 | $ | 0.05 | |||||||||
| Granted | 740,000 | 0.07 | ||||||||||
| Exercised | (18,750 | ) | (0.03 | ) | - | |||||||
| Cancelled | - | - | - | |||||||||
| Outstanding September 30, 2021 | 3,355,500 | $ | 0.06 | |||||||||
| Exercisable September 30, 2021 | 2,085,041 | $ | 0.04 | |||||||||
In connection with the grant of stock options the Company recognizes the value of the related option expense using the Black Scholes model, with appropriate assumptions for option life, stock value, risk free interest rate, volatility, and cancellations.
SCHEDULE OF FAIR VALUE ASSUMPTIONS - STOCK OPTIONS
| September 30, 2021 | March 31, 2021 | |||||||
| Stock Price at grant date | $ | 0.07 | $ | - $ | ||||
| Exercise Price | $ | 0.07 | $ | - $ | ||||
| Term in Years | - | - | ||||||
| Volatility assumed | % | % - | % | |||||
| Annual dividend rate | % | % | ||||||
| Risk free discount rate | % | % - | % | |||||
The compensation expense calculated at time of grant is recognized over the vesting period for the options granted. During the three and six months ended September 30, 2021 the Company recognized $and $, respectively, as stock-based compensation expense. For the corresponding three and six months ended September 30, 2020, the Company recognized $and $, respectively.
The intrinsic value of outstanding options at September 30, 2021 was $, and $of the option expense upon grant remained unrecognized at September 30, 2021 with a remaining vesting period of years.
| 26 |
D) WARRANTS
In conjunction with the sale of Series A Stock Units, the Company issued 4,200,000 warrants to purchase common stock at a price of $1.20 per share for a period of three years. The Company did not bifurcate the value of the warrants as the fair value of the warrant was determined to be de minimis. The Company has not issued any warrants since September, 2019. At September 30, 2021 and March 31, 2021 the fair value of the warrants was de minimis.
SCHEDULE OF WARRANTS
| Number of warrants | Weighted average exercise price | Weighted average remaining life in years | ||||||||||
| Outstanding March 31, 2020 | 4,200,000 | $ | 1.20 | |||||||||
| Granted | - | - | - | |||||||||
| Exercised | (2,603,333 | ) | $ | 1.20 | - | |||||||
| Cancelled | - | - | - | |||||||||
| Outstanding September 30, 2020 | 1,596,667 | $ | 1.20 | |||||||||
| Exercisable March 31, 2020 | 4,200,000 | $ | 1.20 | |||||||||
| Exercisable September 30, 2020 | 1,596,667 | $ | 1.20 | |||||||||
| Number of warrants | Weighted average exercise price | Weighted average remaining life in years | ||||||||||
| Outstanding March 31, 2021 | 1,596,667 | $ | 1.20 | |||||||||
| Granted | - | - | ||||||||||
| Exercised | - | - | ||||||||||
| Cancelled | - | - | ||||||||||
| Outstanding September 30, 2021 | 1,596,667 | $ | 1.20 | |||||||||
| Exercisable March 31, 2021 | 1,596,667 | $ | 1.20 | |||||||||
| Exercisable September 30, 2021 | 1,596,667 | $ | 1.20 | |||||||||
The Company values the warrants using the Black Scholes model, with appropriate assumptions for warrant life, stock value, risk free interest rate, and volatility. The assumptions used for warrant valuation were as follows:
SCHEDULE OF FAIR VALUE ASSUMPTIONS - STOCK OPTIONS
| Stock Price at grant date | $ | 0.006 | ||
| Exercise Price | $ | 1.200 | ||
| Term in Years | ||||
| Volatility assumed | % | |||
| Annual dividend rate | % | |||
| Risk free discount rate | % |
��
| 27 |
NOTE 7 – FINANCIAL HIGHLIGHTS
SCHEDULE OF FINANCIAL HIGHLIGHTS
| Per share data ( a) | Three months ended | Three months ended | Six months ended | Six months ended | ||||||||||||
September 30, 2021 | September 30, 2020 | September 30, 2021 | September 30, 2020 | |||||||||||||
| Net asset value | $ | 0.82 | $ | 0.72 | $ | 0.82 | $ | 0.72 | ||||||||
| Net investment loss | $ | (0.03 | ) | $ | (0.03 | ) | $ | (0.06 | ) | $ | (0.03 | ) | ||||
| Net unrealized gain on investments | $ | 0.10 | $ | 0.05 | $ | 0.11 | $ | 0.08 | ||||||||
| Net increase in net assets | $ | 0.08 | $ | 0.05 | $ | 0.05 | $ | 0.05 | ||||||||
| Ratios and Supplemental Data | ||||||||||||||||
| Net assets, end of period | $ | 10,817,894 | $ | 4,230,731 | $ | 10,817,894 | $ | 4,230,731 | ||||||||
| Weighted average common shares outstanding, end of period | 13,271,996 | 5,836,832 | 13,269,764 | 5,836,832 | ||||||||||||
| Total operating expenses/net assets | 3.3 | % | 3.8 | % | 6.8 | % | 4.7 | % | ||||||||
| Net investment loss/net assets | 3.3 | % | 3.8 | % | 6.8 | % | 4.7 | % | ||||||||
| Total return | 9.2 | % | 7.5 | % | 6.1 | % | 6.6 | % | ||||||||
| (a) | Per share data is based on the weighted average number of common shares outstanding at the end of the period. |
NOTE 8 - SUBSEQUENT EVENTS
On October 5, 2021, the Company filed a Form 8-K announcing the Designation of million shares of B-3 Preferred Stock. As of November 13, 2021, the Company has sold $546,000 of shares of Series B-3 Preferred Stock and invested $300,000 in three follow-on investments.
| ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS |
PLAN OF OPERATIONS
Kyto Technology and Life Science, Inc. (the “Company”) was formed as a going concern due to substantial recurring losses from operations, cash used in operations, stockholders’ deficit, significant accumulated deficit and working capital deficit. Our ability to continue as a going concern will be determined by our ability to obtain additional financing and maintain operations. Currently we do not have sufficient financial resources to fund our operations. Therefore, we need additional funds to continue these operations. The Company operates in a rapidly changing environment that involves a numberFlorida corporation on March 5, 1999 under the name of factors, some of which are beyond management’s control, such as financial market trends and investors’ appetite for new financings. It should be emphasized that, shouldB Twelve, Inc. In August, 2002, the Company not be successful in completingchanged its own financing (either by debt or by the issuance of securitiesname from treasury), the Company may be unableB Twelve, Inc. to continue to operate as a going concern.
The Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases and had been evaluating a number of strategies. As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior operations. In April 2018, the Board adopted a new business plan focused on the development of early-stage technology and life science businesses through early stage investment funding. The Company has recruited a number of experienced investment consultants from a network that includes angel investors, corporate managers, sophisticated early stage investors and successful entrepreneurs with experience across a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. The Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally, it is expected that investments will be changedrealized from an exit within a period of four to five years following initial investment. Such exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions or an initial public offering (“IPO”) which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. Other than making its initial and, potentially, follow-on investments in its portfolio companies, the Company does not provide any financial support to any of its investees.
| 28 |
The Company has one regular employee – the CEO, Mr, Paul Russo. Prior to December 31, 2020, was acting as a symbolconsultant to the Company and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged as agreed to by OTCQB.
The Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of the date of this filing, the Company had approximately $485,000 of cash to cover its operating expenses, and new investment requirements, and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a changegoing concern. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the OfficersCompany’s business operations, although some of its portfolio investment companies report delays in their programs.
At March 31, 2020, management determined that the Company was an investment company for purposes of ASC 946 disclosure, and Directorscommitted to follow the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the SEC. KI is an internally managed, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of KPBH. The officers1940, as amended (the “1940 Act”). Immediately upon effectiveness of this N-2 Registration Statement, the Company will merge with KI and directors of KBPH at closingthe Company will be the surviving entity. As of the Private Placementcompletion of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the merger, the Company had fewer than 100 non-affiliated investors and filed under the 1934 Act relying on exemption Rule 3( c )(1).
As a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for U.S. federal income tax purposes as follows:
Results of Operations
Revenue: In the three months and six months ended September 30, 2021 the Company reported no realized investment income as there were no liquidity events related to its investment portfolio. The Company reported $1,350,449 and $1,403,415 of unrealized gains from investments respectively, in these periods. In the three months and six months ended September 30, 2020 the Company reported no realized investment income as there were no liquidity events related to its investment portfolio. The Company reported $478,248 of unrealized gains from investments respectively, in these same periods.
.
Professional fees: In the three months and six months ended September 30, 2021, the Company reported $107,201 and $273,359, respectively, of professional fees, mainly for legal and accounting services. In the corresponding three months and six months ended September 30, 2020 the Company reported $63,605 and $76,543, respectively.
Other Operating expenses: Other operating expenses include payroll, consulting, and travel and conference fees associated with raising capital and review of Operations
For the three months and six months ended December 31, 2017September 30, 2021, the Company’s net loss attributable to common shareholders decreased by $6,946 to $24,133 compared to aincrease in net loss of $31,079 forassets resulting from operations was $996,133 and $662,341, respectively. For the corresponding three months and six months ended September 30, 2020, the Company’s net increase in net assets resulting from operations was $318,137 and $279,269, respectively.
During the three months ended December 31, 2016.
Liquidity and Capital Resources
The Company had working capital deficitsnet assets of $289,991 as of December 31, 2017$10,817,894 and $226,129 as of$6,993,163 at September 30, 2021 and March 31, 2017.2021, respectively. Cash was $76 as of December 31, 2017,$316,124 and Nil as of$1,437,868 at September 30, 2021 and March 31, 2017.
Cash from operating activities
The Company’sCompany used net cash of $3,071,238 in operating activities during the six months ended September 30, 2021 compared to $909,564 used for the six months ended September 30, 2020. Main reasons for the higher level in 2021 were an increase in investments in portfolio companies and increased professional fees and operating expenses.
Cash from investing activities
No cash was used in operations decreased by $8,425 to $20,884 for the nine months ended December 31, 2017 compared to net cash used in operations of $29,309 for the nine months ended December 31, 2016.
Cash from financing activities
The Company’sCompany had a net cash flows from financing activities decreased by $8,326 to $20,960 for the nine months ended December 31, 2017 compared to cash flowsinflow from financing activities of $29,286 for$1,949,494 in the ninesix months ended December 31, 2016.
The Company’s plan of operations for the next twelve months is to continue to focus its efforts on finding new sources of capital by means of private placements, and on R&D activities relatedto use this capital to fund additional investments as they become available, and to cover operating expenses. The Company is planning to uplift from OTC to the developmentNASDAQ market, and applicationraise additional funding from an initial public offering (“IPO)” for which as an initial step it has submitted an N-2 filing to the SEC for review.
| 30 |
CRITICAL ACCOUNTING POLICIES
USE OF ESTIMATES
In preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period presented. Actual results may differ from these estimates.
Significant estimates at September 30, 2021 and March 31, 2021 include the valuation of investments, deferred tax assets, tax allowance, stock options and warrants.
INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE
The Company reviews the performance of its antibody technologies. investments based on available information, including management reports, press releases, web site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports, to determine their fair values. In the event that Management considers the fair value of an investment to be greater or less than the current book value, the difference will be reflected as unrealized gains or losses in investments in the statements of operations.
The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing GAAP that require the use of fair value measurements which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.
The Company has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed and approved. The Company uses observable market data to estimate the fair value of investments to the extent that market data is available. In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active, the Company uses the valuation methodologies described below with unobservable data based on the best available information in the circumstances, which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.
For investments for which quoted market prices are not available, which comprise most of our investment portfolio, fair value is estimated by using the income, market, or back-solve approach. The income approach is based on the assumption that value is created by the expectation of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive those future benefits. The market approach compares recent comparable transactions to the investment. The back solve method involves comparing available data over a period of time and inferring a new valuation based on changes from a known starting point, for example the cost of an investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These valuation methodologies involve a significant degree of judgment on the part of our management and board.
In determining the appropriate fair value of an investment using these approaches, the most significant information and assumptions may include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral, the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business, comparisons of financial ratios of peer companies that are public, merger and acquisition comparables, the principal market and enterprise values, environmental factors, subsequent financings by the portfolio investment, among other factors.
The estimated fair values do not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments, the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments existed.
| 31 |
RECENT ACCOUNTING PRONOUNCEMENTS
Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.
OFF-BALANCE SHEET ARRANGEMENTS
As of the date of filing of this Quarterly Report on Form 10-Q, we do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.
IMPACT OF INFLATION
The Company does not foresee any implications being created by the current rate of inflation.
CONTRACTUAL OBLIGATION
The Company has no contractual obligations outside the normal course of business with the U.S. Securitiesits vendors, advisors, and Exchange Commission, the Company did receive a commitment of one of its stockholders to continue to provide operating loan funds to the Company.
| ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
Not required for smaller reporting company.
| ITEM 4. | CONTROLS AND PROCEDURES |
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to our management, including our chief executive officer/chief financial officer (principal financial officer) as appropriate, to allow timely decisions regarding required disclosure. During the quarterthree months ended December 31, 2017September 30, 2021 we carried out an evaluation, under the supervision and with the participation of our management, including the principal executive officer and the chiefprincipal financial officer (principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rule 13(a)-15(e) under the 1934 Act. Based on this evaluation, because of the Company’s limited resources and limited number of employees, management concluded that our disclosure controls and procedures were ineffective as of December 31, 2017.
Management’s Report on Internal Control over Financial Reporting
With the participation of our Chief Executive Officer and Chief Financial Officer (principal financial officer), our management conducted an evaluation of the effectiveness of our internal control over financial reporting as of September 30, 2021 based on the framework in Internal Controls—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on our evaluation and the material weaknesses described below, management concluded that the Company did not maintain effective internal control over financial reporting as of September 30, 2021 based on the COSO framework criteria. Management has identified control deficiencies regarding the lack of segregation of duties and the need for a stronger internal control environment. Management of the Company believes that these material weaknesses are due to the small size of the Company’s accounting staff. The small size of the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit of such remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight of transactions, along with the use of external legal and accounting professionals. As we grow, we expect to increase our number of employees, which will enable us to implement adequate segregation of duties within the internal control framework. In addition, we have identified the following material weaknesses: (i) the Company utilizes accounting software that does not prevent erroneous or unauthorized changes to previous reporting periods and/or can be adjusted so as not to provide an adequate audit trail of entries made in the accounting software, and (ii) we have identified a material weakness in our internal controls relating to the accounting of transactions that are either highly complex and/or unusual in nature. In such instances, we seek to augment our internal accounting capabilities by obtaining assistance from third-parties who have greater expertise in such areas.
These control deficiencies could result in a misstatement of account balances that would result in a reasonable possibility that a material misstatement to our financial statements may not be prevented or detected on a timely basis. Accordingly, we have determined that these control deficiencies as described above together constitute a material weakness. However, management believes that despite our material weaknesses, our financial statements for the three and six month periods ended September 30, 2021 are fairly stated, in all material respects, in accordance with US GAAP.
Limitations on Effectiveness of Controls and Procedures
Our management, including our Chief Executive Officer and Chief Financial Officer (principal financial officer), does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
| 32 |
PART II. OTHER INFORMATION
| ITEM 1. | LEGAL PROCEEDINGS |
None
| ITEM 1A. | RISK FACTORS. |
Not required for smaller reporting company.
| ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS. |
The Corporation filed a certificate of Designation in April 2021 for the issue of up to 3,200,000 shares of Series B-1 Preferred stock to accredited investors under Section 4(2) or Rule 506 of Regulation D of the Securities Act 1933. As of the filing date, the Corporation had sold a total of 5,911,416 shares of Series B Preferred stock to accredited investors. The Company will use the net proceeds for investment purposes and operating expenses.
| ITEM 3. | DEFAULTS UPON SENIOR SECURITIES |
None
| ITEM 4. | MINE SAFETY DISCLOSURES |
Not applicable
| ITEM 5. | OTHER INFORMATION |
None
| ITEM 6. | EXHIBITS |
Index to Exhibits on page 13
| 33 |
INDEX TO EXHIBITS
| EXHIBIT NUMBER | DESCRIPTION | |
| 3 (i) (a) | Articles of Incorporation of Kyto | |
| Articles of Amendment changing name to Kyto | ||
| Bylaws of Kyto | ||
| Section 302 | ||
| 32.1 | ||
| Certification pursuant to 18 |
| * | Filed as Exhibit to Company’s Form 10-SB on September 12, 2003 with the Securities and Exchange Commission. |
| ** | Previously filed with Form 8-K on July 17, 2019. |
| *** | Filed as Exhibit with Form 10-K on July 2, 2020. |
| 34 |
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Kyto | ||
| By: | /s/ Paul Russo | |
Paul Russo Chief Executive Officer, principal executive officer, | ||
Date: November 18, 2021
SIGNATURES
In accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Kyto Technology and Life Science, Inc. | ||
| By: | /s/ Simon Westbrook | |
Simon Westbrook Principal financial and accounting officer | ||
Date: November 18, 2021
| 35 |